UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 28, 2020
PARKERVISION, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
Florida
|
000-22904
|
59-2971472
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
9446
Philips Highway, Suite 5A, Jacksonville, Florida
|
32256
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(904) 732-6100
(Registrant’s
Telephone Number, Including Area Code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
Title
of Each Class
|
Trading
Symbol
|
Name of
Each Exchange on Which Registered
|
Common
Stock, $.01 par value
|
PRKR
|
OTCQB
|
Common
Stock Rights
|
|
OTCQB
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e 4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter.
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item
1.01.Entry into a Material Definitive Agreement.
Warrant Agreement Amendment
On
February 28, 2020, the Company entered into a warrant amendment
agreement (the “Warrant Amendment
Agreement”) with Aspire Capital Fund, LLC
(“Aspire”), with respect to
warrants issued in July and September 2018 that are exercisable,
collectively, into 5,000,000 shares of the Company’s common
stock (the “Existing Warrants”). The Warrant Amendment
Agreement provides for a reduction in the exercise price for the
Existing Warrants from $0.74 to $0.35 per share and the issuance of
a new warrant for the purchase of 5,000,000 shares of the
Company’s common stock at an exercise price of $0.74 per
share (the “New
Warrants”).
The
Warrant Amendment Agreement also adds a call provision to the
Existing Warrants whereby the Company may, after December 31, 2020,
call for cancellation of all or any portion of the Existing
Warrants for which an exercise notice has not yet been received, in
exchange for consideration equal to $0.001 per warrant share and
subject to certain conditions, including the continued existence of
an effective registration statement for the underlying warrant
shares and the availability of sufficient authorized shares to
allow for the exercise of the Existing Warrants. All other terms of
the Existing Warrants remain unchanged, including the original
expiration dates of July and September 2023. In connection with the
Warrant Amendment Agreement, Aspire exercised a portion of the
Existing Warrants for net proceeds to the Company of approximately
$0.5 million.
The New
Warrants expire five years after issuance and have substantially
similar other terms to the Existing Warrants, except for exercise
price. The Existing Warrants and New Warrants, collectively, the
“Warrants” are subject to adjustment in the event of
certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting the
Company’s common stock and also upon any distributions of
assets to the Company’s stockholders. The New Warrants
contain provisions that prohibit exercise if the holder, together
with its affiliates, would beneficially own in excess of 9.99% of
the number of shares of the Company’s common stock
outstanding immediately after giving effect to such exercise. The
holder of the New Warrants may increase (up to 19.99%) or decrease
this percentage by providing at least 61 days’ prior notice
to the Company. In the event of certain corporate transactions, the
holder of the Warrants will be entitled to receive, upon exercise
of such Warrants, the kind and amount of securities, cash or other
property that the holders would have received had they exercised
the Warrants immediately prior to such transaction. The Warrants do
not contain voting rights or any of the other rights or privileges
as a holder of the Company’s common stock.
The
Company has agreed to file a registration statement as permissible
and necessary to register under the Securities Act of 1933, as
amended, the resale by Aspire of the shares of the Company’s
common stock and the shares of the Company’s common stock
underlying the New Warrants. The shares underlying the Existing
Warrants are currently registered pursuant to a registration
statement on Form S-1 (File No. 333-226738).
The
foregoing description of the terms and conditions of the Warrant
Amendment Agreement, the Existing Warrants and the New Warrants are
not complete and are qualified in their entirety by the full text
of the Warrant Amendment Agreement and form of warrant, which are
filed herewith as Exhibits 10.1 and 4.1, respectively, and
incorporated into this Item 1.01 by reference.
Private
Placement of Common Stock
On
March 5, 2020,the Company entered into subscription agreement s
(the “Subscription
Agreement”) providing for the sale of an aggregate of
1,714,286 shares (“Shares”) of the
Company’s common stock, par value $0.01 per share, at a price
of $0.35 per share, to accredited investors. The Subscription
Agreement contains customary representations and warranties of the
purchaser. The $600,000 in proceeds from the sale of the Shares
will be used to fund the Company’s operations.
The
Company also entered into registration rights agreement (the
“PIPE Registration
Rights Agreement”) with the investors pursuant to
which the Company will register the Shares. The Company has
committed to file the registration statement by the 60th calendar day
following the closing date and to cause the registration statement
to become effective by the 120th calendar day
following the closing date. The PIPE Registration Rights Agreement
provides for liquidated damages upon the occurrence of certain
events including failure by the Company to file the registration
statement or cause it to become effective by the deadlines set
forth above. The amount of the liquidated damages is 1.0% of the
aggregate subscription upon the occurrence of the event, and
monthly thereafter, up to a maximum of 6%.
The
Shares were offered and sold to accredited investors on a private
placement basis under Section 4(a)(2) of the Securities Act of
1933, as amended, and Rule 506 promulgated thereunder.
The
foregoing summaries of the Purchase Agreement and the PIPE
Registration Rights Agreement are qualified in their entirety by
reference to the full text of the agreements, which are attached as
part of Exhibits 10.2 through 10.3 hereto and are incorporated
herein by reference.
Repayment of Promissory Note
On
February 28, 2020, the Company issued an aggregate of 1,526,426
unregistered shares of the Company’s Common Stock
(“Repayment
Shares”) as an in-kind payment of approximately
$237,000 in outstanding principal and accrued interest on a May 15,
2019 promissory note with the Thomas Staz Revocable
Trust.
Item
3.02.Unregistered Sales of Equity Securities.
The
disclosures included in Item 1.01 regarding the shares underlying
the New Warrants, the shares subject to the Subscription Agreement
and the Repayment Shares are incorporated herein by reference to
the extent required.
Item
9.01.Financial Statements and Exhibits.
|
|
Exhibit
No.
|
Description
|
4.1
|
|
10.1
|
|
10.2
|
|
10.3
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
Dated:
March 5, 2020
|
|
|
|
|
PARKERVISION, INC.
|
|
|
|
|
|
By /s/ Cynthia
Poehlman
|
|
|
Cynthia Poehlman
|
|
|
Chief Financial Officer
|
WARRANT AMENDMENT
AGREEMENT
WARRANT AMENDMENT AGREEMENT (the
“Agreement”),
dated as of February 28, 2020, by and between PARKERVISION, INC., a Florida
corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois
limited liability company (“Aspire”). Capitalized terms used
herein and not otherwise defined herein are defined in Section 9
hereof.
WHEREAS:
Aspire is the holder of a warrant
(No. 2018-02, dated 7/26/2018) and another warrant (No. 2018-04,
dated 9/11/2018) (collectively referred to as the “Existing
Warrants”) exercisable, collectively, into a
total of 5,000,000 shares of Common Stock (the “Existing Warrants Shares”)
which Existing Warrants are currently registered pursuant to a
registration statement on Form S-1 (File No. 333-226738). The
Company wishes to induce Aspire to exercise some or all of the
Existing Warrants, by amending the exercise price in the Existing
Warrants and issuing to Aspire new warrants (the “New
Warrants”), substantially in the form attached
hereto as Exhibit A (the “New
Warrants Certificate”) to purchase shares of
Common Stock (collectively, the “New
Warrant Shares”). The New Warrants and the New
Warrant Shares are collectively referred to herein as the
“Securities.”
NOW THEREFORE, the Company and Aspire
hereby agree as follows:
1.
AMENDMENT
AND EXERCISE OF EXISTING WARRANTS; ISSUANCE OF NEW
WARRANTS.
(a)
Existing Warrants Amendment.
The Existing Warrants exercise price is hereby amended to $0.35
effective immediately, subject to further adjustment as described
in the Existing Warrants. The Company and Aspire hereby agree the
underlying shares of the Company’s Common Stock previously
reserved for issuance upon exercise of the Existing Warrants shall
no longer be required to be reserved. A new Section 15(i) is
inserted and made part of each of the Existing Warrants as
follows:
(i)
Call Provision. The
Company may, on any Trading Day after December 31, 2020, call for
cancellation of all or any portion of this Warrant for which an
Exercise Notice has not yet been delivered (such right, a
“Call”) for consideration equal to $0.001 per Warrant
Share. To exercise this right, the Company must deliver to the
Holder an irrevocable written notice (a “Call Notice”),
indicating therein the portion of unexercised portion of this
Warrant to which such notice applies. If the conditions set forth
below for such Call are and remain satisfied from the period from
the date of the Call Notice through and including the Call Date (as
defined below), then any portion of this Warrant subject to such
Call Notice for which an Exercise Notice shall not have been
received by the Call Date will be cancelled at 6:30 p.m. New York
City time on the tenth Trading Day after the date the Call Notice
is received by the Holder (such date and time, the “Call
Date”). Any unexercised portion of this Warrant to which the
Call Notice does not pertain will be unaffected by such Call
Notice. In furtherance thereof, the Company covenants and agrees
that it will honor all Exercise Notices with respect to Warrant
Shares subject to a Call Notice that are tendered through 6:30 p.m.
New York City time on the Call Date. The parties agree that any
Exercise Notice delivered following a Call Notice which calls less
than all of the Warrants shall first reduce to zero the number of
Warrant Shares subject to such Call Notice prior to reducing the
remaining Warrant Shares available for purchase under this Warrant.
For example, if (A) this Warrant then permits the Holder to acquire
100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant
Shares, and (C) prior to 6:30 p.m. New York City time on the Call
Date the Holder tenders an Exercise Notice in respect of 50 Warrant
Shares, then (x) on the Call Date the right under this Warrant to
acquire 25 Warrant Shares will be automatically cancelled, (y) the
Company, in the time and manner required under this Warrant, will
have issued and delivered to the Holder 50 Warrant Shares in
respect of the exercises following receipt of the Call Notice, and
(z) the Holder may, until the Expiration Date, exercise this
Warrant for 25 Warrant Shares (subject to adjustment as herein
provided and subject to subsequent Call Notices). Subject again to
the provisions of this Section 15(i), the Company may deliver
subsequent Call Notices for any portion of this Warrant for which
the Holder shall not have delivered an Exercise Notice.
Notwithstanding anything to the contrary set forth in this Warrant,
the Company may not deliver a Call Notice or require the
cancellation of this Warrant (and any such Call Notice shall be
void), unless all of the following conditions are and remain
satisfied from the period from the date of the Call Notice through
and including the Call Date: (1) the Company shall have honored in
accordance with the terms of this Warrant all Exercise Notices
delivered by 6:30 p.m. New York City time on the Call Date; (2) a
registration statement shall be effective as to all Warrant Shares
and the prospectus thereunder available for use by the Company for
the sale of all such Warrant Shares to the Holder; (3) the Warrant
Shares shall be listed or quoted for trading on the Principal
Trading Market; (4) the Company has sufficient number of authorized
Common Stock and the directors of the Company have authority to
allot a sufficient number of Common Stock to provide for the
issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant; (5) the issuance of all Warrant Shares
subject to a Call Notice shall not cause a breach of any of the
provisions of Section 11 herein; and (6) the Holder is not in
possession of any information that constitutes, or might
constitute, material non-public information which was provided by
the Company, any of its Subsidiaries, or any of their officers,
directors, employees, agents or Affiliates.
(b) Existing
Warrants exercise. Upon execution of this Agreement, Aspire
shall exercise a portion of the Existing Warrants (as amended by
this Agreement) equal to at least 1,430,000 Existing Warrants
Shares and $500,500 proceeds.
(c) Issuance
of New Warrants. Upon execution of this Agreement, the
Company shall issue to Aspire, and Aspire shall receive from the
Company, an additional 5,000,000 New Warrants in the form of the
New Warrants Certificate.
2. ASPIRE’S
REPRESENTATIONS AND WARRANTIES.
Aspire
hereby represents and warrants to the Company that:
(a) Investment
Purpose. Aspire is entering into this Agreement and
acquiring the Securities for its own account for investment;
provided however, by making the representations herein, Aspire does
not agree to hold any of the Securities for any minimum or other
specific term.
(b) Accredited
Investor Status. Aspire is an “accredited
investor” as that term is defined in Rule 501(a)(3) of
Regulation D of the Securities Act of 1933, as amended (the
“1933
Act”).
(c) Reliance
on Exemptions. Aspire understands that the Securities are
being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and
state securities laws and that the Company is relying in part upon
the truth and accuracy of, and Aspire's compliance with, the
representations, warranties, agreements, acknowledgments and
understandings of Aspire set forth herein in order to determine the
availability of such exemptions and the eligibility of Aspire to
acquire the Securities.
(d) Information.
Aspire has been furnished with all materials relating to the
business, finances and operations of the Company and materials
relating to the offer and sale of the Securities that have been
reasonably requested by Aspire. Aspire understands that its
investment in the Securities involves a high degree of risk. Aspire
(i) is able to bear the economic risk of an investment in the
Securities including a total loss, (ii) has such knowledge and
experience in financial and business matters that it is capable of
evaluating the merits and risks of the proposed investment in the
Securities and (iii) has had an opportunity to ask questions of and
receive answers from the officers of the Company concerning the
financial condition and business of the Company and other matters
related to an investment in the Securities. Neither such inquiries
nor any other due diligence investigations conducted by Aspire or
its representatives shall modify, amend or affect Aspire’s
right to rely on the Company’s representations and warranties
contained in Section 3 below. Aspire has sought such accounting,
legal and tax advice as it has considered necessary to make an
informed investment decision with respect to its acquisition of the
Securities.
(e) No
Governmental Review. Aspire understands that no United
States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or
endorsement of the Securities or the fairness or suitability of the
investment in the Securities nor have such authorities passed upon
or endorsed the merits of the offering of the
Securities.
(f) Transfer
or Sale. Aspire understands that: (i) the Securities have
not been registered under the 1933 Act or any state securities
laws, and may not be offered for sale, sold, assigned or
transferred unless (A) subsequently registered thereunder or (B) an
exemption exists permitting such Securities to be sold, assigned or
transferred without such registration; (ii) any sale of the
Securities made in reliance on Rule 144 may be made only in
accordance with the terms of Rule 144 and further, if Rule 144 is
not applicable, any resale of the Securities under circumstances in
which the seller (or the person through whom the sale is made) may
be deemed to be an underwriter (as that term is defined in the 1933
Act) may require compliance with some other exemption under the
1933 Act or the rules and regulations of the U.S. Securities and
Exchange Commission (the “SEC”); and (iii) neither the
Company nor any other person is under any obligation to register
the Securities under the 1933 Act or any state securities laws or
to comply with the terms and conditions of any exemption
thereunder.
(g) Organization.
Aspire is a limited liability company duly organized and validly
existing in good standing under the laws of the jurisdiction in
which it is organized, and has the requisite organizational power
and authority to own its properties and to carry on its business as
now being conducted.
(h) Validity;
Enforcement. This Agreement has been duly and validly
authorized, executed and delivered on behalf of Aspire and is a
valid and binding agreement of Aspire enforceable against Aspire in
accordance with its terms, subject as to enforceability to (i)
general principles of equity and to applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement
of applicable creditors’ rights and remedies and (ii) public
policy underlying any law, rule or regulation (including any
federal or state securities law, rule or regulation) with regards
to indemnification, contribution or exculpation. The execution and
delivery of the this Agreement by Aspire and the consummation by it
of the transaction contemplated hereby do not conflict with
Aspire’s certificate of organization or operating agreement
or similar documents, and do not require further consent or
authorization by Aspire, its managers or its members.
(i) Residency.
Aspire is a resident of the
State of Illinois.
3. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.
The
Company represents and warrants to Aspire that:
(a) Organization
and Qualification. The Company and its
“Subsidiaries” (which for purposes of this Agreement
means any entity in which the Company, directly or indirectly, owns
more than 50% of the voting
stock or capital stock or other similar equity interests) are
corporations or limited liability companies duly organized and
validly existing in good standing under the laws of the
jurisdiction in which they are incorporated or organized, and have
the requisite corporate or organizational power and authority to
own their properties and to carry on their business as now being
conducted. Each of the Company and its Subsidiaries is duly
qualified as a foreign corporation or limited liability company to
do business and is in good standing in every jurisdiction in which
its ownership of property or the nature of the business conducted
by it makes such qualification necessary, except to the extent that
the failure to be so qualified or be in good standing could not
reasonably be expected to have a Material Adverse Effect. As used
in this Agreement, “Material
Adverse Effect” means any material adverse effect on
any of: (i) the business, properties, assets, operations, results
of operations or financial condition of the Company and its
Subsidiaries, if any, taken as a whole, or (ii) the authority or
ability of the Company to perform its obligations under the this
Agreement.
(b) Authorization;
Enforcement; Validity. (i) The Company has the requisite
corporate power and authority to enter into and perform its
obligations under this Agreement, and the New Warrants and to issue
the Securities in accordance with the terms hereof, (ii) the
execution and delivery of this Agreement and the New Warrants by
the Company and the consummation by it of the transaction
contemplated hereby, including without limitation, the issuance of
the Securities under this Agreement, have been duly authorized by
the Company’s Board of Directors or duly authorized committee
thereof, do not conflict with the Company’s Certificate of
Incorporation or Bylaws (as defined below), and do not require
further consent or authorization by the Company, its Board of
Directors, except as set forth in this Agreement, or its
stockholders, (iii) this Agreement has been duly executed and
delivered by the Company and (iv) this Agreement constitutes the
valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, except as such enforceability
may be limited by (y) general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement
of creditors' rights and remedies and (z) public policy underlying
any law, rule or regulation (including any federal or state
securities law, rule or regulation) with regards to
indemnification, contribution or exculpation. The Board of
Directors of the Company or duly authorized committee thereof has
approved the resolutions (the “Signing Resolutions”)
substantially in the form as delivered to Aspire to authorize this
Agreement and the transaction contemplated hereby. The Signing
Resolutions are valid, in full force and effect and have not been
modified or supplemented in any material respect. The Company has
delivered to Aspire a true and correct copy of the Signing
Resolutions as approved by the Board of Directors of the Company or
an appropriate Board committee.
(c) Authorization
of the Securities. The Securities have been duly authorized
and, upon issuance in accordance with the terms hereof, the
Securities shall be (i) validly issued, fully paid and
non-assessable and (ii) free from all taxes, liens and charges with
respect to the issuance thereof, with the holders being entitled to
all rights accorded to a holder of Common Stock. The New Warrants
have been duly authorized by the Company and, when executed and
delivered by the Company, will be valid and binding agreements of
the Company, enforceable against the Company in accordance with
their terms, except as the enforcement thereof may be limited by
bankruptcy, insolvency, reorganization, moratorium or other similar
laws relating to or affecting the rights and remedies of creditors
or by general equitable principles. The New Warrant Shares have
been duly authorized and validly reserved for issuance upon
exercise of the New Warrants in a number sufficient to meet the
current exercise requirements. The New Warrant Shares, when issued
and delivered upon exercise of the New Warrants in accordance
therewith, shall be (i) validly issued, fully paid and
non-assessable and (ii) free from all taxes, liens and charges with
respect to the issuance thereof, with the holders being entitled to
all rights accorded to a holder of Common Stock.
(d) No
Conflicts. The execution, delivery and performance of this
Agreement and the issuance of the Securities by the Company and the
consummation by the Company of the transactions contemplated hereby
(including, without limitation, the reservation for issuance and
issuance of the New Warrant Shares), does not and will not (i)
result in a violation of the Certificate of Incorporation, any
Certificate of Designations, Preferences and Rights of any
outstanding series of preferred stock of the Company or the Bylaws
or (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or
instrument to which the Company or any of its Subsidiaries is a
party, or result, to the Company’s knowledge, in a violation
of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws and regulations applicable to the
Company or any of its Subsidiaries) or by which any property or
asset of the Company or any of its Subsidiaries is bound or
affected. Neither the Company nor its Subsidiaries is in violation
of any term of or in default under its Certificate of
Incorporation, including any Certificate of Designation,
Preferences and Rights of any outstanding series of preferred stock
of the Company, or Bylaws or their organizational charter or
bylaws, respectively. Neither the Company nor any of its
Subsidiaries is in violation of any term of or is in default under
any material contract, agreement, mortgage, indebtedness,
indenture, instrument, judgment, decree or order or any statute,
rule or regulation applicable to the Company or its Subsidiaries,
except for possible violations, defaults, terminations or
amendments that could not reasonably be expected to have a Material
Adverse Effect. The business of the Company and its Subsidiaries is
not being conducted, and shall not be conducted, in violation of
any law, ordinance, or regulation of any governmental entity,
except for possible violations, the sanctions for which either
individually or in the aggregate could not reasonably be expected
to have a Material Adverse Effect. Except as specifically
contemplated by this Agreement, reporting obligations under the
Securities & Exchange Act of 1934 (the “1934 Act”) or as required under
the 1933 Act or applicable state securities laws, the Company is
not required to obtain any consent, authorization or order of, or
make any filing or registration with, any court or governmental
agency or any regulatory or self-regulatory agency in order for it
to execute, deliver or perform any of its obligations under or
contemplated by the this Agreement in accordance with the terms
hereof. Except for the reporting obligations under the 1934 Act,
all consents, authorizations, orders, filings and registrations
which the Company is required to obtain pursuant to the preceding
sentence shall be obtained or effected on or prior to the date
hereof.
4. COVENANTS.
(a) Filing
of Form 8-K and Registration Statement. The Company agrees
that it shall, within four business day under the 1934 Act, file a
Current Report on Form 8-K disclosing this Agreement and the
transaction contemplated hereby. If the Company files a
registration statement to register any of its Common Stock, the
Company shall also include the New Warrant Shares in such new
registration statement in order to cover the resale of the New
Warrant Shares by Aspire (the “Registration
Statement”).
(b) New
Warrant Shares Reserved. The Company shall, at all times
while any New Warrants are outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to
issue New Warrant Shares upon exercise of such New Warrants, the
number of New Warrant Shares that are initially issuable and
deliverable upon the exercise of the then-outstanding New
Warrants.
5. MISCELLANEOUS.
(a) Governing
Law; Jurisdiction; Jury Trial. The corporate laws of the
State of Florida shall govern all issues concerning the relative
rights of the Company and its stockholders. All other questions
concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by the internal
laws of the State of Illinois, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State
of Illinois or any other jurisdictions) that would cause the
application of the laws of any jurisdictions other than the State
of Illinois. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of
Chicago, for the adjudication of any dispute hereunder or in
connection herewith or therewith, or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in
an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in
any such suit, action or proceeding by mailing a copy thereof to
such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY.
(b) Counterparts.
This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party; provided
that a facsimile or pdf (or other
electronic reproduction) signature shall be considered due
execution and shall be binding upon the signatory thereto with the
same force and effect as if the signature were an original, not a
facsimile or PDF (or other electronic
reproduction) signature.
(c) Headings.
The headings of this Agreement are for convenience of reference and
shall not form part of, or affect the interpretation of, this
Agreement.
(d) Severability.
If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of
the remainder of this Agreement in that jurisdiction or the
validity or enforceability of any provision of this Agreement in
any other jurisdiction.
(e) Entire
Agreement. This Agreement supersede all other prior oral or
written agreements between Aspire, the Company, their affiliates
and persons acting on their behalf with respect to the matters
discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as
specifically set forth herein or therein, neither the Company nor
Aspire makes any representation, warranty, covenant or undertaking
with respect to such matters. Each of the Company and Aspire
acknowledges and agrees that it has not relied on, in any manner
whatsoever, any representations or statements, written or oral,
other than as expressly set forth in this Agreement.
(f) Notices.
Any notices, consents or other communications required or permitted
to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party);
(iii) upon receipt, when sent by electronic message (provided the
recipient responds to the message and confirmation of both
electronic messages are kept on file by the sending party); or (iv)
one (1) business day after timely deposit with a nationally
recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and
facsimile numbers for such communications shall be:
If to
the Company:
ParkerVision,
Inc.
9446
Philips Highway, Suite 5A
Jacksonville, FL
32256
Telephone: 904-732-6100
Facsimile: 904-330-0111
Attention: Cynthia
Poehlman, CFO
Email: cpoehlman@parkervision.com
With a
copy (which shall not constitute notice) to:
Graubard
Miller
The
Chrysler Building
405
Lexington Avenue, 11th Floor
New
York, New York 10174
Attention:
Paul A.
Lucido
Email:
plucido@graubard.com
If to
Aspire:
Aspire
Capital Fund, LLC
155
North Wacker Drive, Suite 1600
Chicago, IL
60606
Attention:
Steven G.
Martin
Email:
smartin@aspirecapital.com
With a
copy to (which shall not constitute delivery to
Aspire):
Morrison &
Foerster LLP
2000
Pennsylvania Avenue, NW, Suite 6000
Washington, DC
20006
Attention:
Martin P. Dunn,
Esq.
If to
the Transfer Agent:
American Stock
Transfer & Trust Company
6201
15th Avenue
Brooklyn, NY
11219
Attention:
Christine
Pino
Email:
cpino@astfinancial.com
or at
such other address and/or facsimile number and/or to the attention
of such other person as the recipient party has specified by
written notice given to each other party at least one (1) business
day prior to the effectiveness of such change. Written confirmation
of receipt (A) given by the recipient of such notice, consent or
other communication, (B) mechanically or electronically generated
by the sender’s facsimile machine containing the time, date,
and recipient facsimile number, (C) electronically generated by the
sender’s electronic mail containing the time, date and
recipient email address or (D) provided by a nationally recognized
overnight delivery service, shall be rebuttable evidence of receipt
in accordance with clause (i), (ii), (iii) or (iv) above,
respectively.
(g) Successors
and Assigns. This Agreement shall be binding upon and inure
to the benefit of the parties and their respective successors and
assigns. The Company shall not assign this Agreement or any rights
or obligations hereunder without the prior written consent of
Aspire, including by merger or consolidation; provided, however,
that any transaction, whether by merger, reorganization,
restructuring, consolidation, financing or otherwise, whereby the
Company remains the surviving entity immediately after such
transaction shall not be deemed a succession or assignment. Aspire
may not assign its rights or obligations under this
Agreement.
(h) No
Third Party Beneficiaries. This Agreement is intended for
the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any
provision hereof be enforced by, any other person.
(i) Publicity.
Aspire shall have the right to approve before issuance any press
release, SEC filing or any other public disclosure made by or on
behalf of the Company whatsoever with respect to, in any manner,
Aspire, its purchases hereunder or any aspect of this Agreement or
the transactions contemplated hereby; provided, however, that the
Company shall be entitled, without the prior approval of Aspire, to
make any press release or other public disclosure (including any
filings with the SEC) with respect to such transactions as is
required by applicable law and regulations so long as the Company
and its counsel consult with Aspire in connection with any such
press release or other public disclosure at least one (1) business
day prior to its release; provided, however, that the
Company’s obligations pursuant to this Section 10(i) shall
not apply if the material provisions of such press release, SEC
filing, or other public disclosure previously has been publicly
disclosed by the Company in accordance with this Section 5(i).
Aspire must be provided with a copy thereof at least one (1)
business day prior to any release or use by the Company
thereof.
(j) Further
Assurances. Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates,
instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the
purposes of this Agreement and the consummation of the transactions
contemplated hereby.
(k) No
Financial Advisor, Placement Agent, Broker or Finder. The
Company represents and warrants to Aspire that it has not engaged
any financial advisor, placement agent, broker or finder in
connection with the transactions contemplated hereby. Aspire
represents and warrants to the Company that it has not engaged any
financial advisor, placement agent, broker or finder in connection
with the transactions contemplated hereby. Each party shall be
responsible for the payment of any fees or commissions, if any, of
any financial advisor, placement agent, broker or finder engaged by
such party relating to or arising out of the transactions
contemplated hereby. Each party shall pay, and hold the other party
harmless against, any liability, loss or expense (including,
without limitation, attorneys' fees and out of pocket expenses)
arising in connection with any such claim.
(l) No
Strict Construction. The language used in this Agreement
will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be
applied against any party.
(m)
Failure or Indulgence Not
Waiver. No failure or delay in the exercise of any power,
right or privilege hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any
other right, power or privilege.
*
* * * *
IN WITNESS WHEREOF, Aspire and the
Company have caused this Warrant Amendment Agreement to be duly
executed as of the date first written above.
THE COMPANY:
PARKERVISION,
INC.
By:______________________
Name:
Jeffrey Parker
Title:
CEO
ASPIRE:
ASPIRE
CAPITAL FUND, LLC
BY:
ASPIRE CAPITAL PARTNERS, LLC
BY:
By:_______________________
Name:
Title:
SECURITIES PURCHASE AGREEMENT
This
Securities Purchase Agreement (this “Agreement”) is dated as
of March 5, 2020 between ParkerVision, Inc., a Florida corporation
(the “Company”), and each
purchaser identified on the signature pages hereto (each, including
its successors and assigns, a “Purchaser” and
collectively, the “Purchasers”).
WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant
to Section 4(2) of the Securities Act of 1933, as amended (the
“Securities
Act”), and Rule 506 promulgated thereunder, the
Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this
Agreement.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in
this Agreement, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Company
and each Purchaser agree as follows:
ARTICLE I.
DEFINITIONS
1.1 Definitions.
In addition to the terms defined elsewhere in this Agreement, for
all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:
“Action” shall have the
meaning ascribed to such term in Section 3.1(i).
“Affiliate” means any
Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed
under Rule 405 under the Securities Act.
“Board of Directors” means
the board of directors of the Company.
“Business Day” means any
day except Saturday, Sunday, any day which is a federal legal
holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by
law or other governmental action to close.
“Closing” means the
closing of the purchase and sale of the Securities pursuant to
Section 2.1.
“Closing Date” means the
Trading Day when all of the Transaction Documents have been
executed and delivered by the applicable parties thereto, and all
conditions precedent to (i) the Purchasers’ obligations to
pay the Subscription Amount and (ii) the Company’s
obligations to deliver the Securities have been satisfied or
waived.
“Commission” means the
United States Securities and Exchange Commission.
“Common Stock” means the
common stock of the Company, par value $0.01 per share, and any
other class of securities into which such securities may hereafter
be reclassified or changed into.
“Common Stock Equivalents”
means any securities of the Company or any subsidiary which would
entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock.
“Company Counsel” means
Graubard Miller, with offices located at The Chrysler Building, 405
Lexington Avenue, New York, New York 10174.
“Disclosure Schedules”
means the Disclosure Schedules of the Company delivered
concurrently herewith.
“Effective Date” means the
earliest of the date that (a) the Registration Statement has been
declared effective by the Commission, (b) all of the Shares have
been sold pursuant to Rule 144 or may be sold pursuant to Rule 144
or (c) the one year anniversary of the Closing Date provided that
all of the Shares may be sold pursuant to an exemption from
registration under Section 4(1) of the Securities Act (assuming,
for the purpose of making this determination, that all of the
holders of the Shares are non-Affiliates of the Company) and
Company Counsel has delivered to such holders a standing written
unqualified opinion that resales may then be made by such holders
of the Shares pursuant to such exemption which opinion shall be in
form and substance reasonably acceptable to such
holders.
“Evaluation
Date” shall have the meaning ascribed to such term in
Section 3.1(q).
“Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
“GAAP”
shall have the meaning ascribed to such term in Section
3.1(g).
“Indebtedness” shall have
the meaning ascribed to such term in Section 3.1(y).
“Intellectual Property”
shall have the meaning ascribed to such term in Section
3.1(n).
“Legend Removal Date”
shall have the meaning ascribed to such term in Section
4.1(c).
“Lien” means a lien,
charge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction.
“Material Adverse Effect”
shall have the meaning assigned to such term in Section
3.1(a).
“Material Permits” shall
have the meaning ascribed to such term in Section
3.1(l).
“Per Share Purchase Price”
equals $0.35, subject to
adjustment for reverse and forward stock splits, stock dividends,
stock combinations and other similar transactions of the Common
Stock that occur after the date of this Agreement and prior to the
Closing Date.
“Person” means an
individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“Proceeding” means an
action, claim, suit, investigation or proceeding (including,
without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or
threatened.
“Public Information
Failure” shall have the meaning ascribed to such term
in Section 4.2(b).
“Public Information Failure
Payments” shall have the meaning ascribed to such term
in Section 4.2(b).
“Purchaser Party” shall
have the meaning ascribed to such term in Section 4.8.
“Registration Rights
Agreement” means the Registration Rights Agreement,
dated the date hereof, among the Company and the Purchasers, in the
form of Exhibit A
attached hereto.
“Registration Statement”
means a registration statement meeting the requirements set forth
in the Registration Rights Agreement and covering the resale by the
Purchasers of the Shares.
“Required Approvals” shall
have the meaning ascribed to such term in Section
3.1(d).
“Rule 144” means Rule 144
promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially
the same effect as such Rule.
“SEC Reports” shall have
the meaning ascribed to such term in Section 3.1(g).
“Securities” means the
Shares.
“Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.
“Shares” means the shares
of Common Stock issued or issuable to each Purchaser pursuant to
this Agreement.
“Short Sales” means all
“short sales” as defined in Rule 200 of Regulation SHO
under the Exchange Act (but shall not
be deemed to include the location and/or reservation of borrowable
shares of Common Stock).
“Subscription Amount”
means, as to each Purchaser, the aggregate amount to be paid for
Shares purchased hereunder as specified below such
Purchaser’s name on the signature page of this Agreement and
next to the heading “Subscription Amount,” in United
States dollars and in immediately available funds.
“Trading
Day” means a day on which the principal Trading Market
is open for trading.
“Trading Market” means the
following markets or exchanges on which the Common Stock is listed
or quoted for trading on the date in question: the NYSE American,
the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq
Global Select Market, the New York Stock Exchange or the
Over-the-Counter Bulletin Board (the OTCQB, the OTCQX or the
“Pink Sheets” published by The OTC Markets Group, Inc.
or a similar organization or agency succeeding to its functions or
reporting prices), or any successors to any of the
foregoing.
“Transaction Documents”
means this Agreement, the Registration Rights Agreement, all
exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions
contemplated hereunder.
“Transfer Agent” means
American Stock Transfer and Trust Company, the current transfer
agent of the Company, with a mailing address of 6201 15th Avenue,
Brooklyn, NY 11219, and any successor transfer agent of the
Company.
ARTICLE II.
PURCHASE AND SALE
2.1 Closing.
On the Closing Date, upon the terms and subject to the conditions
set forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company
agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of [∙] Shares. Each Purchaser shall deliver to the
Company via wire transfer of immediately available funds equal to
its Subscription Amount and the Company shall deliver to each
Purchaser its respective Shares, as determined pursuant to Section
2.2(a), and the Company and each Purchaser shall deliver the other
items set forth in Section 2.2 deliverable at the Closing. Upon
satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at the offices of Company
Counsel or such other location as the parties shall mutually
agree.
Deliveries.
(a) On or prior to the
Closing Date, the Company shall deliver or cause to be delivered to
each Purchaser the following:
(i) this Agreement duly
executed by the Company;
(ii) a
copy of the irrevocable instructions to the Transfer Agent
instructing the Transfer Agent to issue to the Purchaser that
number of Shares equal to such Purchaser’s Subscription
Amount divided by the Per Share Purchase Price, registered in the
name of such Purchaser;
(iii) the
Registration Rights Agreement duly executed by the
Company.
(b) On or prior to the
Closing Date, each Purchaser shall deliver or cause to be delivered
to the Company the following:
(i) this Agreement duly
executed by such Purchaser;
(ii) such
Purchaser’s Subscription Amount by wire transfer to the
account as specified in writing by the Company; and
(iii) the
Registration Rights Agreement duly executed by such
Purchaser.
2.2 Closing
Conditions.
(a) The
obligations of the Company hereunder in connection with the Closing
are subject to the following conditions being
met:
(i) the accuracy in all
material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all
respects) on the Closing Date of the representations and warranties
of the Purchasers contained herein (unless as of a specific date
therein in which case they shall be accurate as of such
date);
(ii) all
obligations, covenants and agreements of each Purchaser required to
be performed at or prior to the Closing Date shall have been
performed; and
(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b)
of this Agreement.
(b) The respective obligations of the Purchasers hereunder in
connection with the Closing are subject to the following conditions
being met:
(i) the accuracy in all
material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all
respects) when made and on the Closing Date of the representations
and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of
such date);
(ii) all
obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing Date shall have been
performed;
(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of
this Agreement.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES
3.1 Representations
and Warranties of the Company.
Except as set forth in the Disclosure Schedules, which Disclosure
Schedules shall be deemed a part hereof and shall qualify any
representation or otherwise made herein to the extent of the
disclosure contained in the corresponding section of the Disclosure
Schedules, the Company hereby makes the following representations
and warranties to each Purchaser:
(a) Subsidiaries; Organization and
Qualification. All of the direct and indirect subsidiaries
of the Company are set forth on Schedule 3.1(a). The Company owns,
directly or indirectly, all of the capital stock or other equity
interests of each Subsidiary free and clear of any Liens, and all
of the issued and outstanding shares of capital stock of each
Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or
purchase securities. The Company and each of its subsidiaries is an
entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its
incorporation or organization (as applicable), with the requisite
power and authority to own and use its properties and assets and to
carry on its business as currently conducted. Neither the Company
nor any subsidiary is in violation or default of any of the
provisions of its articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company and its
subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the
case may be, could not have or reasonably be expected to result in
(i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or
condition (financial or otherwise) of the Company, taken as a
whole, or (iii) a material adverse effect on the Company’s
ability to perform in any material respect its obligations under
any Transaction Document (any of (i), (ii) or (iii), a
“Material Adverse
Effect”), and no Proceeding has been instituted in any
such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such power and authority or
qualification.
(b) Authorization; Enforcement. The
Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this
Agreement and each of the other Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Board of
Directors or the Company’s stockholders in connection
herewith or therewith other than in connection with the Required
Approvals. This Agreement and each other Transaction Document to
which it is a party has been (or upon delivery will have been) duly
executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(c) No Conflicts. The execution,
delivery and performance by the Company of this Agreement and the
other Transaction Documents by the Company, the issuance and sale
of the Securities and the consummation by the Company of the other
transactions contemplated hereby and thereby do not and will not
(i) conflict with or violate any provision of the Company’s
articles of incorporation, bylaws or other organizational or
charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become
a default) under, result in the creation of any Lien upon any of
the properties or assets of the Company under, or give to others
any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company
debt or otherwise) or other understanding to which the Company is a
party or by which any property or asset of the Company is bound or
affected, or (iii) subject to the Required Approvals, conflict with
or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company is subject (including
federal and state securities laws and regulations), or by which any
property or asset of the Company is bound or affected; except in
the case of each of clauses (ii) and (iii), such as could not have
or reasonably be expected to result in a Material Adverse
Effect.
(d) Filings, Consents and
Approvals. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or
make any filing or registration with, any court or other federal,
state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than (i) such filings,
if any, as are required to be made under applicable Federal and
state securities laws, including the filings required pursuant to
Section 4.4, the filing with the Commission of a Registration
Statement and the filing with the Commission of a Form D, (ii) such
notices or applications, if any, as are required to be given or
made to the Trading Market for the issuance and sale of the
Securities and the listing of the Shares for trading thereon and
(iii) such filings as are required to be made under applicable
state securities laws (the “Required
Approvals”).
(e) Issuance of the Securities. The
Securities are duly authorized and, when issued and paid for in
accordance with the applicable Transaction Documents, will be duly
and validly issued, fully paid and nonassessable, free and clear of
all Liens imposed by the Company other than restrictions on
transfer provided for in the Transaction Documents. The Company has
reserved from its duly authorized capital stock the maximum number
of shares of Common Stock issuable pursuant to this
Agreement.
(f) Capitalization. Capitalization. The
capitalization of the Company as of the date hereof is as set forth
on Schedule 3.1(f)
of the Disclosure Schedules. Except as set forth in the SEC Reports
or Schedule 3.1(f),
the Company has not issued any capital stock since its most recently filed periodic report under the
Exchange Act, other than pursuant to the exercise of
employee stock options and the vesting of restricted stock units
under the Company’s equity incentive plans and pursuant to
the conversion or exercise or exchange of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first
refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the
Transaction Documents. Except as set forth in the SEC Reports or
Schedule 3.1(f) and
except for outstanding awards under the Company’s equity
incentive plans, there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire any shares of Common
Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or
any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents or capital stock of any
Subsidiary. The issuance and sale of the Securities will not
obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers)
and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under
any of such securities. There are no outstanding securities or
instruments of the Company or any Subsidiary that contain any
redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or
any Subsidiary is or may become bound to redeem a security of the
Company or such Subsidiary. All of the outstanding shares of
capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in compliance with
all federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or
others is required for the issuance and sale of the Securities.
There are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company’s capital
stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s
stockholders.
(g) SEC Reports; Financial
Statements. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by it
under the Securities Act and the Exchange Act, including pursuant
to Section 13(a) or 15(d) thereof, for the two years preceding the
date hereof (or such shorter period as the Company was required by
law or regulation to file such material) (the foregoing materials
filed prior to the date hereof, including the exhibits thereto and
documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely
basis or has received a valid extension of such time of filing and
has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Securities
Act and the Exchange Act and the rules and regulations of the
Commission promulgated thereunder, and none of the SEC Reports,
when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The
financial statements of the Company included in the SEC Reports
comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with
respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with United States
generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be
otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company as of and
for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit
adjustments.
(h) Material Changes; Undisclosed Events,
Liabilities or Developments. Since the date of the latest
audited financial statements included within the SEC Reports,
except as specifically disclosed in the SEC Reports, (i) there has
been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii)
the Company has not incurred any liabilities (contingent or
otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or required
to be disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or
other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital
stock, except in connection with the payment of the exercise price
of, or withholding taxes for, awards under the Company’s
equity incentive plans, and (v) the Company has not issued any
equity securities to any officer, director or Affiliate, except
pursuant to the Company’s existing equity incentive plans.
The Company does not have pending before the Commission any request
for confidential treatment of information. Except for the issuance
of the Securities contemplated by this Agreement, no event,
liability, fact, circumstance, occurrence or development has
occurred or exists with respect to the Company or its business,
properties, operations, financial condition or prospects that would
be required to be publicly disclosed by the Company under
applicable securities laws at the time this representation is made
that has not been publicly disclosed at least one (1) Trading Day
prior to the date that this representation is made.
(i) Litigation. Except as set forth
in the SEC Reports, there is no action, suit, inquiry, notice of
violation, Proceeding or investigation pending or, to the knowledge
of the Company, threatened against or affecting the Company or any
of its properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an “Action”) which (i)
adversely affects or challenges the legality, validity or
enforceability of any of the Transaction Documents or the
Securities or (ii) could, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse
Effect. Neither the Company, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of
violation of or liability under federal or state securities laws or
a claim of breach of fiduciary duty. To the knowledge of the
Company, there is not pending or contemplated, any investigation by
the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued
any stop order or other order suspending the effectiveness of any
registration statement filed by the Company under the Exchange Act
or the Securities Act.
(j) Labor Relations. No material
labor dispute exists or, to the knowledge of the Company, is
imminent with respect to any of the employees of the Company which
could reasonably be expected to result in a Material Adverse
Effect. None of the Company’s employees is a member of a
union that relates to such employee’s relationship with the
Company, and the Company is not a party to a collective bargaining
agreement, and the Company believes that its relationship with its
employees is good. No executive officer of the Company, to the
knowledge of the Company, is, or is now expected to be, in
violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or
any restrictive covenant, and the continued employment of each such
executive officer does not subject the Company to any liability
with respect to any of the foregoing matters. The Company is in
compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(k) Compliance. The Company (i) is
not in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or
both, would result in a default by the Company under), nor has the
Company received notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such
default or violation has been waived), (ii) is not in violation of
any judgment, decree or order of any court, arbitrator or other
governmental authority, or (iii) is not and has not been in
violation of any statute, rule or regulation of any governmental
authority, including without limitation all foreign, federal, state
and local laws applicable to its business and all such laws that
affect the environment, except in each case as could not reasonably
be expected to result in a Material Adverse Effect.
(l) Environmental
Laws. The
Company and its Subsidiaries (i) are in compliance with all
federal, state, local and foreign laws relating to pollution or
protection of human health or the environment (including ambient
air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases
or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively,
“Hazardous
Materials”) into the environment, or otherwise
relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands,
or demand letters, injunctions, judgments, licenses, notices or
notice letters, orders, permits, plans or regulations, issued,
entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required
of them under applicable Environmental Laws to conduct their
respective businesses; and (iii) are in compliance with all terms
and conditions of any such permit, license or approval where in
each clause (i), (ii) and (iii), the failure to so comply could be
reasonably expected to have, individually or in the aggregate, a
Material Adverse Effect.
(m) Regulatory Permits. The Company
possesses all certificates, authorizations and permits issued by
the appropriate federal, state, local or foreign regulatory
authorities necessary to conduct its business as described in the
SEC Reports, except where the failure to possess such permits could
not reasonably be expected to result in a Material Adverse Effect
(“Material
Permits”), and the Company has not received any notice
of proceedings relating to the revocation or modification of any
Material Permit.
(n) Title to Assets. The Company
has good and marketable title in fee simple to all real property
owned by it that is material to the business of the Company and
good and marketable title in all personal property owned by it that
is material to the business of the Company, in each case free and
clear of all Liens, except for Liens as do not materially affect
the value of such property and do not materially interfere with the
use made and proposed to be made of such property by the Company
and Liens for the payment of federal, state or other taxes, the
payment of which is neither delinquent nor subject to penalties.
Any real property and facilities held under lease by the Company
are held by it under valid, subsisting and enforceable leases with
which the Company is in compliance.
(o) Intellectual Property. The
Company owns, possesses, or can acquire on reasonable terms, all
Intellectual Property necessary for the conduct of its business as
now conducted or as described in the SEC Reports to be conducted,
except as such failure to own, possess, or acquire such rights
would not result in a Material Adverse Effect. Except as set forth
in the SEC Reports, (i) to the knowledge of the Company, there is
no infringement, misappropriation or violation by third parties of
any such Intellectual Property, except as such infringement,
misappropriation or violation would not result in a Material
Adverse Effect; (ii) there is no pending or, to the knowledge of
the Company, threatened action, suit, proceeding or claim by others
challenging the Company’s rights in or to any such
Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such claim; (iii) the
Intellectual Property owned by the Company and to the knowledge of
the Company, the Intellectual Property licensed to the Company has
not been adjudged invalid or unenforceable, in whole or in part,
and there is no pending or threatened action, suit, proceeding or
claim by others challenging the validity or scope of any such
Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such claim; (iv) there
is no pending or threatened action, suit, proceeding or claim by
others that the Company infringes, misappropriates or otherwise
violates any Intellectual Property or other proprietary rights of
others, the Company has not received any written notice of such
claim, and the Company is unaware of any other fact which would
form a reasonable basis for any such claim; and (v) to the
Company’s knowledge, no employee of the Company is in or has
ever been in violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement,
non-competition agreement, non-solicitation agreement,
nondisclosure agreement or any restrictive covenant to or with a
former employer where the basis of such violation relates to such
employee’s employment with the Company or actions undertaken
by the employee while employed with the Company, except as such
violation would not result in a Material Adverse Effect.
“Intellectual
Property” shall mean all patents, patent applications,
trade and service marks, trade and service mark registrations,
trade names, copyrights, licenses, inventions, trade secrets,
technology, know-how and other intellectual property.
(p) Insurance. The Company is
insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and
customary in the businesses in which the Company is engaged,
including, but not limited to, directors and officers insurance
coverage. The Company has no reason to believe that it will not be
able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a
significant increase in cost.
(q) Transactions With Affiliates and
Employees. Except as set forth in the SEC Reports, none of
the officers or directors of the Company and, to the knowledge of
the Company, none of the employees of the Company is presently a
party to any transaction with the Company (other than for services
as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the
Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director,
trustee or partner, in each case in excess of $120,000, other than
for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including equity awards under
any equity incentive plans of the Company.
(r) Sarbanes-Oxley. The Company is
in compliance with any and all requirements of the Sarbanes-Oxley
Act of 2002 that are applicable to the Company, and any and all
rules and regulations promulgated by the Commission thereunder,
that are applicable to the Company and effective as of the date
hereof and as of the Closing Date. The Company maintains a system
of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset
accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific
authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. The
Company has established disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
Company and designed such disclosure controls and procedures to
ensure that information required to be disclosed by the Company in
the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the
effectiveness of the disclosure controls and procedures of the
Company as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the
“Evaluation
Date”). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the
Evaluation Date. Since the Evaluation Date, there have been no
changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company that have
materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the
Company.
(s) Certain Fees. No brokerage or
finder’s fees or commissions are or will be payable by the
Company to any broker, financial advisor or consultant, finder,
placement agent, investment banker, bank or other Person with
respect to the transactions contemplated by the Transaction
Documents. The Purchasers shall have no obligation with respect to
any fees or with respect to any claims made by or on behalf of
other Persons for fees of a type contemplated in this Section that
may be due in connection with the transactions contemplated by the
Transaction Documents.
(t) Private Placement. Assuming the
accuracy of the Purchasers’ representations and warranties
set forth in Section 3.2, no registration under the Securities Act
is required for the offer and sale of the Securities by the Company
to the Purchasers as contemplated hereby. The issuance and sale of
the Securities hereunder does not contravene the rules and
regulations of the Trading Market.
(u) Investment Company. The Company
is not, and is not an Affiliate of, and immediately after receipt
of payment for the Securities, will not be or be an Affiliate of,
an “investment company” within the meaning of the
Investment Company Act of 1940, as amended. The Company shall
conduct its business in a manner so that it will not become an
“investment company” subject to registration under the
Investment Company Act of 1940, as amended.
(v) Registration Rights. Other than
with respect to the Company’s existing registration
statements filed under the Securities Act, or as otherwise
disclosed in the SEC Reports or Schedule 3.1(v) and other than
each of the Purchasers, no Person has any right to cause the
Company or any Subsidiary to effect the registration under the
Securities Act of any securities of the Company or any
Subsidiaries.
(w) Listing and Maintenance
Requirements. The Company’s Common Stock is registered
pursuant to Section 12(b) of the Exchange Act. Except as disclosed
in the SEC Reports or otherwise publicly disclosed in a Company
press release, the Company has not, in the 12 months preceding the
date hereof, received notice from any Trading Market on which the
Common Stock is or has been listed or quoted to the effect that the
Company is not in compliance with the maintenance requirements of
such Trading Market. The Common Stock is currently eligible for
electronic transfer through the Depository Trust Company or another
established clearing corporation and the Company is current in
payment of the fees to the Depository Trust Company (or such other
established clearing corporation) in connection with such
electronic transfer.
(x) Disclosure. Except with respect
to the material terms and conditions of the transactions
contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has
provided any of the Purchasers or their agents or counsel with any
information that it believes constitutes or might constitute
material, non-public information. The Company understands and
confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the
Company. All of the disclosure furnished by or on behalf of the
Company to the Purchasers regarding the Company and its
Subsidiaries, their respective businesses and the transactions
contemplated hereby, including the Disclosure Schedules to this
Agreement, is true and correct and does not contain any untrue
statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the
light of the circumstances under which they were made, not
misleading. .
(y) Tax Status. Except for matters
that could not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect, the Company (i)
has made or filed all necessary federal, state, foreign and local
income and franchise tax returns, reports and declarations required
by any jurisdiction to which it is subject, (ii) has paid all taxes
and other governmental assessments and charges that are material in
amount, shown or determined to be due on such returns, reports and
declarations and (iii) has set aside on its books provision
reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or
declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for
any such claim.
(z) Foreign Corrupt Practices.
Neither the Company nor any Subsidiary, nor to the knowledge of the
Company or any Subsidiary, any agent or other person acting on
behalf of the Company or any Subsidiary, has (i) directly or
indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or
domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any
foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the
Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law
or (iv) violated in any material respect any provision of
FCPA.
(aa) Accountants.
The Company’s accounting firm is Moore Stephens Lovelace,
P.A. To the knowledge of the Company, such accountants, who the
Company expects will express their opinion with respect to the
financial statements to be included in the Company’s next
Annual Report on Form 10-K, are a registered public accounting firm
as required by the Securities Act.
(bb) Acknowledgment
Regarding Purchasers’ Purchase of Securities. The
Company acknowledges and agrees that each of the Purchasers is
acting solely in the capacity of an arm’s length purchaser
with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no
Purchaser is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated thereby and
any advice given by any Purchaser or any of their respective
representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely
incidental to the Purchasers’ purchase of the Securities. The
Company further represents to each Purchaser that the
Company’s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent
evaluation of the transactions contemplated hereby by the Company
and its representatives.
(cc) Acknowledgement
Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere
herein to the contrary notwithstanding (except for Sections 3.2(g)
and 4.12 hereof), it is understood and acknowledged by the Company
that: (i) none of the Purchasers has been asked by the Company to
agree, nor has any Purchaser agreed, to desist from purchasing or
selling, long and/or short, securities of the Company, or
“derivative” securities based on securities issued by
the Company or to hold the Securities for any specified term; (ii)
past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or
“derivative” transactions, before or after the closing
of this or future private placement transactions, may negatively
impact the market price of the Company’s publicly-traded
securities; (iii) any Purchaser, and counter-parties in
“derivative” transactions to which any such Purchaser
is a party, directly or indirectly, presently may have a
“short” position in the Common Stock, and (iv) each
Purchaser shall not be deemed to have any affiliation with or
control over any arm’s length counter-party in any
“derivative” transaction. The Company further
understands and acknowledges that (y) one or more Purchasers may
engage in hedging activities at various times during the period
that the Securities are outstanding, and (z) such hedging
activities (if any) could reduce the value of the existing
stockholders’ equity interests in the Company at and after
the time that the hedging activities are being conducted. The
Company acknowledges that such aforementioned hedging activities do
not constitute a breach of any of the Transaction
Documents.
(dd) Regulation
M Compliance. During the applicable restricted period
as defined in Regulation M, the Company has not, and to its
knowledge no one acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the
stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or, paid any compensation for
soliciting purchases of, any of the Securities, or (iii) paid or
agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company.
(ee) No
General Solicitation. Neither the Company nor any person
acting on behalf of the Company has offered or sold any of the
Securities by any form of general solicitation or general
advertising. The Company has offered the Securities for sale only
to the Purchasers and certain other “accredited
investors” within the meaning of Rule 501 under the
Securities Act.
(ff) No
Disqualification Events. With respect to the
Securities to be offered and sold hereunder in reliance on Rule 506
under the Securities Act, none of the Company, any of its
predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the offering
hereunder, any beneficial owner of 20% or more of the
Company’s outstanding voting equity securities, calculated on
the basis of voting power, nor any promoter (as that term is
defined in Rule 405 under the Securities Act) connected with the
Company in any capacity at the time of sale (each, an "Issuer Covered Person" and,
together, "Issuer Covered
Persons") is subject to any of the "Bad Actor"
disqualifications described in Rule 506(d)(1)(i) to (viii) under
the Securities Act (a "Disqualification Event"),
except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its
disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided
thereunder.
(gg) Other
Covered Persons. The Company is not aware of any person
(other than any Issuer Covered Person) that has been or will be
paid (directly or indirectly) remuneration for solicitation of
purchasers in connection with the sale of any Regulation D
Securities.
(hh) Notice
of Disqualification Events. The Company will notify the
Purchasers in writing, prior to the Closing Date of (i) any
Disqualification Event relating to any Issuer Covered Person and
(ii) any event that would, with the passage of time, become a
Disqualification Event relating to any Issuer Covered
Person.
(ii) No
Additional Agreements. The Company has not entered into any
agreement or understanding with any Purchaser or other individual
purchasing Shares with respect to the transactions contemplated
hereby or by any of the other Transaction Documents other than as
specified herein or therein. For the avoidance of doubt, each
Purchaser has the same rights with respect to the purchase of
Shares as each of the other Purchasers other than as explicitly set
forth herein or in any of the other Transaction
Documents.
3.2 Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other
Purchaser, hereby represents and warrants as of the date hereof and
as of the Closing Date to the Company as follows (unless as of a
specific date therein):
(a) Organization; Authority. If
such Purchaser is an entity, such purchaser duly organized, validly
existing and in good standing under the laws of the jurisdiction of
its organization with full right, corporate or partnership power
and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry
out its obligations hereunder and thereunder. If such Purchaser is
an entity, the execution and delivery of the Transaction Documents
and performance by such Purchaser of the transactions contemplated
by the Transaction Documents have been duly authorized by all
necessary corporate or similar action on the part of such
Purchaser. Each Transaction Document to which it is a party has
been duly executed by such Purchaser, and when delivered by such
Purchaser in accordance with the terms hereof, will constitute the
valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by
general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(b) Own Account. Such Purchaser
understands that the Securities are “restricted
securities” and have not been registered under the Securities
Act or any applicable state securities law and is acquiring the
Securities as principal for its own account and not with a view to
or for distributing or reselling such Securities or any part
thereof in violation of the Securities Act or any applicable state
securities law, has no present intention of distributing any of
such Securities in violation of the Securities Act or any
applicable state securities law and has no direct or indirect
arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser’s
right to sell the Securities pursuant to the Registration Statement
or otherwise in compliance with applicable federal and state
securities laws) in violation of the Securities Act or any
applicable state securities law. Such Purchaser is acquiring the
Securities hereunder in the ordinary course of its
business.
(c) Purchaser Status. At the time
such Purchaser was offered the Securities, it was, and as of the
date hereof it is, an “accredited investor” as defined
in Rule 501 under Securities Act.
(d) Experience of Such Purchaser.
Such Purchaser, either alone or together with its representatives,
has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and
risks of the prospective investment in the Securities, and has so
evaluated the merits and risks of such investment. Such Purchaser
is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete
loss of such investment.
(e) General Solicitation. Such
Purchaser is not purchasing the Securities as a result of any
advertisement, article, notice or other communication regarding the
Securities published in any newspaper, magazine or similar media or
broadcast over television or radio or presented at any seminar or
any other general solicitation or general
advertisement.
(f) Access to Information. Such
Purchaser acknowledges that it has had the opportunity to review
the Transaction Documents (including all exhibits and schedules
thereto) and the SEC Reports and has been afforded (i) the
opportunity to ask such questions as it has deemed necessary of,
and to receive answers from, representatives of the Company
concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities;
(ii) access to information about the Company and its financial
condition, results of operations, business, properties, management
and prospects sufficient to enable it to evaluate its investment;
and (iii) the opportunity to obtain such additional information
that the Company possesses or can acquire without unreasonable
effort or expense that is necessary to make an informed investment
decision with respect to the investment.
(g) Certain Transactions
and Confidentiality. Other than
consummating the transactions contemplated hereunder, such
Purchaser has not directly or indirectly, nor has any Person acting
on behalf of or pursuant to any understanding with such Purchaser,
executed any purchases or sales, including Short Sales, of the
securities of the Company during the period commencing from
the time that such Purchaser first received a term sheet (written
or oral) from the Company or any other Person representing the
Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the
execution hereof. Notwithstanding the foregoing, in the case of a
Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such
Purchaser’s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser’s assets,
the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made
the investment decision to purchase the Securities covered by this
Agreement. Other than to other Persons party to this Agreement,
such Purchaser has maintained the confidentiality of all
disclosures made to it in connection with this transaction
(including the existence and terms of this transaction).
Notwithstanding the foregoing, for avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or
preclude any actions, with respect to the identification of the
availability of, or securing of, available shares to borrow in
order to effect short sales or similar transactions in the
future.
ARTICLE IV.
OTHER AGREEMENTS OF THE PARTIES
4.1 Transfer
Restrictions.
(a) The Securities may
only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of Securities other than
pursuant to an effective registration statement or Rule 144, to the
Company or to an Affiliate of a Purchaser or in connection with a
pledge as contemplated in Section 4.1(b), the Company may require
the transferor thereof to provide to the Company an opinion of
counsel selected by the transferor and reasonably acceptable to the
Company, the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred
Securities under the Securities Act. As a condition of transfer,
any such transferee shall agree in writing to be bound by the terms
of this Agreement and the Registration Rights Agreement and shall
have the rights of a Purchaser under this Agreement and the
Registration Rights Agreement.
(b) The Purchasers
agree to the imprinting, so long as is required by this Section
4.1, of a legend on any of the Securities in the following
form:
THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY
A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A
FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR”
AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN
SECURED BY SUCH SECURITIES.
The
Company acknowledges and agrees that a Purchaser may from time to
time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or
all of the Securities to a financial institution that is an
“accredited investor” as defined in Rule 501(a) under
the Securities Act and who agrees to be bound by the provisions of
this Agreement and the Registration Rights Agreement and, if
required under the terms of such arrangement, such Purchaser may
transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval
of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection
therewith. Further, no notice shall be required of such pledge. At
the appropriate Purchaser’s expense, the Company will execute
and deliver such reasonable documentation as a pledgee or secured
party of Securities may reasonably request in connection with a
pledge or transfer of the Securities, including, if the Securities
are subject to registration pursuant to the Registration Rights
Agreement, the preparation and filing of any required prospectus
supplement under Rule 424(b)(3) under the Securities Act or other
applicable provision of the Securities Act to appropriately amend
the list of Selling Stockholders (as defined in the Registration
Rights Agreement) thereunder.
(c) Certificates
evidencing the Shares shall not contain any legend (including the
legend set forth in Section 4.1(b) hereof), (i) while a
registration statement covering the resale of such security is
effective under the Securities Act, (ii) following any sale of such
Shares pursuant to Rule 144 or pursuant to a Registration
Statement, (iii) if such Shares are eligible for sale under Rule
144, without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to
such Securities and without volume or manner-of-sale restrictions,
or (iv) if such legend is not required under applicable
requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the
Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent promptly after such time if required
by the Transfer Agent to effect the removal of the legend
hereunder. The Company agrees that, at such time as such legend is
no longer required under this Section 4.1(c), it will, no later
than three Trading Days following the delivery by a Purchaser to
the Transfer Agent of a certificate representing Shares issued with
a restrictive legend, together with such documents or instruments
as may be required by the Transfer Agent (such third Trading Day,
the “Legend Removal
Date”), deliver or cause to be delivered to such
Purchaser a certificate representing such shares that is free from
all restrictive and other legends. The Company may not make any
notation on its records or give instructions to the Transfer Agent
that enlarge the restrictions on transfer set forth in this Section
4. Certificates for Securities subject to legend removal hereunder
shall be transmitted by the Transfer Agent to the Purchaser by
crediting the account of the Purchaser’s prime broker with
the Depository Trust Company System as directed by such
Purchaser.
(d) Each Purchaser,
severally and not jointly with the other Purchasers, agrees that
such Purchaser will sell any Securities pursuant to either the
registration requirements of the Securities Act, including any
applicable prospectus delivery requirements, or an exemption
therefrom, and that if Securities are sold pursuant to a
Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the
removal of the restrictive legend from certificates representing
Securities as set forth in this Section 4.1 is predicated upon the
Company’s reliance upon this understanding.
4.2 Furnishing
of Information; Public Information.
(a) Until the earliest
of the time that no Purchaser owns Securities, the Company
covenants to maintain the registration of the Common Stock under
Section 12(b) or 12(g) of the Exchange Act and to timely file (or
obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is
not then subject to the reporting requirements of the Exchange
Act.
(b) At any time during the period commencing from the
six (6) month anniversary of the date hereof and ending at such
time that all of the Securities may be sold without the requirement
for the Company to be in compliance with Rule 144(c)(1) and
otherwise without restriction or limitation pursuant to Rule 144,
if the Company (i) shall fail for any reason to satisfy the current
public information requirement under Rule 144(c) or (ii) has ever
been an issuer described in Rule 144 (i)(1)(i) or becomes such an
issuer in the future, and the Company shall fail to satisfy any
condition set forth in Rule 144(i)(2) (a “Public Information
Failure”) then, in addition to such Purchaser’s other
available remedies, the Company shall pay to a Purchaser, in cash,
as partial liquidated damages and not as a penalty, by reason of
any such delay in or reduction of its ability to sell the
Securities, an amount in cash equal to one percent (1.0%) of the
aggregate Subscription Amount of such Purchaser’s Securities
on the day of a Public Information Failure and on every thirtieth
(30th)
day (pro rated for periods totaling less than thirty days)
thereafter until the earlier of (a) the date such Public
Information Failure is cured and (b) such time that such public
information is no longer required for the Purchasers to
transfer the Underlying Shares pursuant to Rule 144, up to a
maximum of three percent (3%) of the aggregate Subscription Amount
of such Purchaser’s Securities on the day of a Public
Information Failure. The payments to which a Purchaser shall be
entitled pursuant to this Section 4.2(b) are referred to herein as
“Public Information Failure Payments.” Public
Information Failure Payments shall be paid on the earlier of (i) the
last day of the calendar month during which such Public Information
Failure Payments are incurred and (ii) the third
(3rd)
Business Day after the event or failure giving rise to the Public
Information Failure Payments is cured. In the event the Company
fails to make Public Information Failure Payments in a timely manner, such Public
Information Failure Payments shall bear interest at the rate of 1.5%
per month (prorated for partial months) until paid in full. Nothing
herein shall limit such Purchaser’s right to pursue actual
damages for the Public Information Failure, and such Purchaser
shall have the right to pursue all remedies available to it at law
or in equity including, without limitation, a decree of specific
performance and/or injunctive relief.
4.3 Intentionally
Omitted.
4.4 Securities
Laws Disclosure; Publicity. The
Company shall no later than 9:30 a.m. (New York City time) on the
4th
Trading Day immediately after the
Closing Date, issue a Current Report on Form 8-K, disclosing the
material terms of the transactions contemplated hereby. From and
after the issuance of such Current Report on Form 8-K to be filed
in accordance with clause (i) of the preceding sentence, the
Company represents to the Purchasers that it shall have publicly
disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its respective officers,
directors, employees or agents in connection with the transactions
contemplated by the Transaction Documents. The Company and each
Purchaser shall consult with each other in issuing any other press
releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press
release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of
any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall
not unreasonably be withheld or delayed, except if such disclosure
is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public
statement or communication. Notwithstanding the foregoing, the
Company shall not publicly disclose the name of any Purchaser or
its investment advisor, or include the name of any Purchaser or its
investment advisor in any filing with the Commission or any
regulatory agency or Trading Market, without the prior written
consent of such Purchaser, except: (a) as required by federal
securities law in connection with (i) any registration statement
contemplated by the Registration Rights Agreement and (ii) the
filing of final Transaction Documents with the Commission and (b)
to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause
(b).
4.5 Shareholder
Rights Plan. No claim will be
made or enforced by the Company or, with the consent of the
Company, any other Person, that any Purchaser is an
“acquiring person” under any control share acquisition,
business combination, poison pill (including any distribution under
a rights agreement) or similar anti-takeover plan or arrangement in
effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or
arrangement, by virtue of receiving Securities under the
Transaction Documents.
4.6 Non-Public
Information. Except with
respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents, which shall be disclosed
pursuant to Section 4.4, the Company covenants and agrees that
neither it, nor any other Person acting on its behalf will provide
any Purchaser or its agents or counsel with any information that
constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto such
Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential.
The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in
securities of the Company. To the extent that the Company delivers
any material, non-public information to a Purchaser without such
Purchaser’s consent, the Company hereby covenants and agrees
that such Purchaser shall not have any duty of confidentiality to
Company or any of its officers, directors, agents, employees or
Affiliates, or a duty to the Company or any of its officers,
directors, agents, employees or Affiliates not to trade on the
basis of, such material, non-public information, provided that the
Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document
constitutes, or contains, material, non-public information
regarding the Company, the Company shall simultaneously file such
notice with the Commission pursuant to a Current Report on Form
8-K. The Company understands and confirms that each Purchaser shall
be relying on the foregoing covenant in effecting transactions in
securities of the Company.
4.7 Use
of Proceeds. The Company shall
use the net proceeds from the sale of the Securities hereunder for
working capital purposes and shall not use such proceeds for: (a)
the redemption of any Common Stock or Common Stock Equivalents or
(b) the settlement of any outstanding
litigation.
4.8 Indemnification
of Purchasers. Subject to the
provisions of this Section 4.8, the Company will indemnify and hold
each Purchaser and its directors, officers, shareholders, members,
partners, employees and agents (and any other Persons with a
functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each
Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and
the directors, officers, shareholders, agents, members, partners or
employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a
“Purchaser
Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid
in settlements, court costs and reasonable attorneys’ fees
and costs of investigation that any such Purchaser Party may suffer
or incur as a result of or relating to (a) any breach of any of the
representations, warranties, covenants or agreements made by the
Company in this Agreement or in the other Transaction Documents or
(b) any action instituted against the Purchaser Parties in any
capacity, or any of them or their respective Affiliates, by any
stockholder of the Company who is not an Affiliate of such
Purchaser Parties, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is
based upon a breach of such Purchaser Party’s
representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser
Parties may have with any such stockholder or any violations by
such Purchaser Parties of state or federal securities laws or any
conduct by such Purchaser Parties which constitutes fraud, gross
negligence, willful misconduct or malfeasance). If any action shall
be brought against any Purchaser Party in respect of which
indemnity may be sought pursuant to this Agreement, such Purchaser
Party shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof with counsel of
its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in
any such action and participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such
Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to
assume such defense and to employ counsel or (iii) in such action
there is, in the reasonable opinion of such separate counsel, a
material conflict on any material issue between the position of the
Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (y) for any
settlement by a Purchaser Party effected without the
Company’s prior written consent, which shall not be
unreasonably withheld or delayed; or (z) to the extent, but only to
the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party’s breach of any of the
representations, warranties, covenants or agreements made by such
Purchaser Party in this Agreement or in the other Transaction
Documents.
4.9 Reservation
of Common Stock. As of the date
hereof, the Company has reserved and the Company shall continue to
reserve and keep available at all times, free of preemptive rights,
a sufficient number of shares of Common Stock for the purpose of
enabling the Company to issue Shares pursuant to this
Agreement
4.10 Listing
of Common Stock. The Company
hereby agrees to use best efforts to maintain the listing or
quotation of the Common Stock on the Trading Market on which it is
currently listed, and concurrently with the Closing, if required,
the Company shall apply to list or quote all of the Shares on such
Trading Market. The Company further agrees, if the Company applies
to have the Common Stock traded on any other Trading Market, it
will then include in such application all of the Shares, and will
take such other action as is necessary to cause all of the Shares
to be listed on such other Trading Market as promptly as possible.
The Company will then take all action reasonably necessary to
continue the listing or quotation and trading of its Common Stock
on a Trading Market and will comply in all respects with the
Company’s reporting, filing and other obligations under the
bylaws or rules of the Trading Market. The Company agrees to
maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another
established clearing corporation, including, without limitation, by
timely payment of fees to the Depository Trust Company or such
other established clearing corporation in connection with such
electronic transfer.
4.11 Equal
Treatment of Purchasers. No
consideration (including any modification of any Transaction
Document) shall be offered or paid to any Person to amend or
consent to a waiver or modification of any provision of any of the
Transaction Documents unless the same consideration is also offered
to all of the parties to the Transaction Documents. For
clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately
by each Purchaser, and is intended for the Company to treat the
Purchasers as a class and shall not in any way be construed as the
Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or
otherwise.
4.12 Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with
the other Purchasers, covenants that neither it, nor any Affiliate
acting on its behalf or pursuant to any understanding with it will
execute any purchases or sales, including Short Sales, of any of
the Company’s securities during the period commencing with
the Discussion Time and ending at such time the transactions
contemplated by this Agreement are first publicly announced as
described in Section 4.4. Each Purchaser, severally and not
jointly with the other Purchasers, covenants that until such time
as the transactions contemplated by this Agreement are publicly
disclosed by the Company as described in Section 4.4, such
Purchaser will maintain the confidentiality of the existence and
terms of this transaction and the information included in the
Transaction Documents and the Disclosure Schedules.
Notwithstanding the foregoing, and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly
acknowledges and agrees that (i) no Purchaser makes any
representation, warranty or covenant hereby that it will not engage
in effecting transactions in any securities of the Company after
the time that the transactions contemplated by this Agreement are
first publicly announced pursuant to Section 4.4, (ii) no Purchaser
shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable
securities laws from and after the time that the transactions
contemplated by this Agreement are first publicly announced as
described in Section 4.4 and (iii) no Purchaser shall have any duty
of confidentiality to the Company or its subsidiaries with respect
to the transactions contemplated by this Agreement after the
issuance of the Current Report on Form 8-K as described in clause
(i) of the first sentence of Section 4.4. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed
investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser’s assets and the
portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of
such Purchaser’s assets, the covenant set forth above shall
only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement.
4.13 Form
D; Blue Sky Filings. The
Company agrees to timely file a Form D with respect to the
Securities as required under Regulation D and to provide a copy
thereof, promptly upon request of any Purchaser. The Company shall
take such action as the Company shall reasonably determine is
necessary in order to obtain an exemption for, or to qualify the
Securities for, sale to the Purchasers at the Closing under
applicable securities or “Blue Sky” laws of the states
of the United States, and shall provide evidence of such actions
promptly upon request of any Purchaser.
4.14 Delivery
of Securities After Closing.
The Company shall deliver, or cause to be delivered, the respective
Securities purchased by each Purchaser to such Purchaser within two
(2) Trading Days of the Closing Date.
ARTICLE V.
MISCELLANEOUS
5.1 Termination.
This Agreement may be terminated by any Purchaser, as to such
Purchaser’s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other
Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth
(5th)
Trading Day following the date hereof; provided,
however,
that such termination will not affect the right of any party to sue
for any breach by the other party (or parties).
5.2 Fees
and Expenses. Except as
expressly set forth in the Transaction Documents to the contrary,
each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other
expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement.
The Company shall pay all Transfer Agent fees, stamp taxes and
other taxes and duties levied in connection with the delivery of
any Securities to the Purchasers.
5.3 Entire
Agreement. The Transaction
Documents, together with the exhibits and schedules thereto,
contain the entire understanding of the parties with respect to the
subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents,
exhibits and schedules.
5.4 Notices.
Any and all notices or other communications or deliveries required
or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the date of
transmission, if such notice or communication is delivered via
facsimile at the facsimile number or email attachment as set forth
on the signature pages attached hereto at or prior to 5:30 p.m.
(New York City time) on a Trading Day, (b) the next Trading Day
after the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or email attachment
as set forth on the signature pages attached hereto on a day that
is not a Trading Day or later than 5:30 p.m. (New York City time)
on any Trading Day, (c) the second (2nd)
Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service or (d) upon actual
receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set
forth on the signature pages attached hereto. To the extent that
any notice provided pursuant to any Transaction Document
constitutes, or contains material, non-public information regarding
the Company, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form
8-K.
5.5 Amendments;
Waivers. No provision of this
Agreement may be waived, modified, supplemented or amended except
in a written instrument signed, in the case of an amendment, by the
Company and the Purchasers holding at least a majority in interest
of the Shares then outstanding or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is
sought. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of any party to
exercise any right hereunder in any manner impair the exercise of
any such right.
5.6 Headings.
The headings herein are for convenience only, do not constitute a
part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.
5.7 Successors
and Assigns. This Agreement
shall be binding upon and inure to the benefit of the parties and
their successors and permitted assigns. The Company may not assign
this Agreement or any rights or obligations hereunder without the
prior written consent of each Purchaser (other than by merger). Any
Purchaser may assign any or all of its rights under this Agreement
to any Person to whom such Purchaser assigns or transfers any
Securities, provided such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of
the Transaction Documents that apply to the
“Purchasers.”
5.8 No
Third-Party Beneficiaries. This
Agreement is intended for the benefit of the parties hereto and
their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any
other Person, except as otherwise set forth in Section
4.8.
5.9 Governing
Law. All questions concerning
the construction, validity, enforcement and interpretation of the
Transaction Documents shall be governed by and construed and
enforced in accordance with the internal laws of the State of New
York, without regard to the principles of conflicts of law thereof.
Each party agrees that all legal Proceedings concerning the
interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents
(whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, partners, members,
employees or agents) shall be commenced exclusively in the state
and federal courts sitting in the City of New York. Each party
hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or
discussed herein (including with respect to the enforcement of any
of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any Action or Proceeding, any claim that it
is not personally subject to the jurisdiction of any such court,
that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in
any such Action or Proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to
it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any other manner permitted by
law. If any party shall commence an Action or Proceeding to enforce
any provisions of the Transaction Documents, then, in addition to
the obligations of the Company under Section 4.10, the prevailing
party in such Action or Proceeding shall be reimbursed by the
non-prevailing party for its reasonable attorneys’ fees and
other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or
Proceeding.
5.10 Survival.
The representations and warranties contained herein shall survive
the Closing and the delivery of the Securities for the applicable
statute of limitations.
5.11 Execution.
This Agreement may be executed in two or more counterparts, all of
which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In
the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file,
such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or
“.pdf” signature page were an original
thereof.
5.12 Severability.
If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms,
provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their
commercially reasonable efforts to find and employ an alternative
means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It
is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of
such that may be hereafter declared invalid, illegal, void or
unenforceable.
5.13 Rescission
and Withdrawal Right.
Notwithstanding anything to the contrary contained in (and without
limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election,
demand or option under a Transaction Document and the Company does
not timely perform its related obligations within the periods
therein provided, then such Purchaser may rescind or withdraw, in
its sole discretion from time to time upon written notice to the
Company, any relevant notice, demand or election in whole or in
part without prejudice to its future actions and
rights.
5.14 Replacement
of Securities. If any
certificate or instrument evidencing any Securities is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation
thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft
or destruction. The applicant for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party
costs (including customary indemnity) associated with the issuance
of such replacement Securities.
5.15 Remedies.
In addition to being entitled to exercise all rights provided
herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific
performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss
incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agrees to waive and not to assert
in any action for specific performance of any such obligation the
defense that a remedy at law would be adequate.
5.16 Payment
Set Aside. To the extent that
the Company makes a payment or payments to any Purchaser pursuant
to any Transaction Document or a Purchaser enforces or exercises
its rights thereunder, and such payment or payments or the proceeds
of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or
preferential, set aside, recovered from, disgorged by or are
required to be refunded, repaid or otherwise restored to the
Company, a trustee, receiver or any other person under any law
(including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the
extent of any such restoration the obligation or part thereof
originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or
such enforcement or setoff had not occurred.
5.17 Independent
Nature of Purchasers’ Obligations and
Rights. The obligations of each
Purchaser under any Transaction Document are several and not joint
with the obligations of any other Purchaser, and no Purchaser shall
be responsible in any way for the performance or non-performance of
the obligations of any other Purchaser under any Transaction
Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Purchaser pursuant thereto,
shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create
a presumption that the Purchasers are in any way acting in concert
or as a group with respect to such obligations or the transactions
contemplated by the Transaction Documents. Each Purchaser shall be
entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall
not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose. Each Purchaser
has been represented by its own separate legal counsel in their
review and negotiation of the Transaction Documents. The Company
has elected to provide all Purchasers with the same terms and
Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by the
Purchasers.
5.18 Liquidated
Damages. The Company’s
obligations to pay any partial liquidated damages or other amounts
owing under the Transaction Documents is a continuing obligation of
the Company and shall not terminate until all unpaid partial
liquidated damages and other amounts have been paid notwithstanding
the fact that the instrument or security pursuant to which such
partial liquidated damages or other amounts are due and payable
shall have been canceled.
5.19 Saturdays,
Sundays, Holidays,
etc. If
the last or appointed day for the taking of any action or the
expiration of any right required or granted herein shall not be a
Business Day, then such action may be taken or such right may be
exercised on the next succeeding Business Day.
5.20 Construction.
The parties agree that each of them and/or their respective counsel
has reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the
effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the
Transaction Documents or any amendments hereto. In addition, each
and every reference to share prices and shares of Common Stock in
any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and
other similar transactions of the Common Stock that occur after the
date of this Agreement.
5.21 WAIVER
OF JURY TRIAL.
IN ANY
ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY
PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND
INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW,
HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
WAIVES FOREVER TRIAL BY JURY.
(Signature Pages Follow)
IN
WITNESS WHEREOF, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated
above.
PARKERVISION,
INC.
By:__________________________________________
Name: Cynthia
Poehlman
Title: Chief
Financial Officer
|
Address
for Notice:
9446
Philips Highway
Suite
5A
Jacksonville, FL
32256
Fax:
(904) 732-6100
|
With a
copy to (which shall not constitute notice):
Graubard
Miller
The
Chrysler Building
405
Lexington Avenue, 11th Floor
New
York, NY 10174
Attention:
David Alan Miller, Esq.
Fax:
(212) 818-8881
|
|
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
[PURCHASER
SIGNATURE PAGES FOLLOW]
[PURCHASER
SIGNATURE PAGE]
IN
WITNESS WHEREOF, the undersigned have caused this Securities
Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated
above.
Name of
Purchaser:
Signature of Authorized Signatory of
Purchaser:
Name of
Authorized Signatory:
Title
of Authorized Signatory:
Email
Address of Authorized Signatory:
Facsimile
Number of Authorized Signatory:
Address
for Notice of Purchaser:
Address
for Delivery of Securities for Purchaser (if not same as address
for notice):
Book entry at American Stock Transfer &
Trust
Subscription
Amount: $_____________
Shares:
_____________
[PURCHASER
SIGNATURE PAGES CONTINUE]
REGISTRATION RIGHTS AGREEMENT
This
Registration Rights Agreement (this “Agreement”) is made and
entered into as of March 5, 2020, between ParkerVision, Inc., a
Florida corporation (the “Company”), and each of
the several purchasers signatory hereto (each such purchaser, a
“Purchaser” and,
collectively, the “Purchasers”).
This
Agreement is made pursuant to the Securities Purchase Agreement,
dated as of the date hereof, between the Company and each Purchaser
(the “Purchase
Agreement”).
The
Company and each Purchaser hereby agrees as follows:
Capitalized
terms used and not otherwise defined herein that are defined in the
Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement. As used in this Agreement, the following
terms shall have the following meanings:
“Advice”
shall have the meaning set forth in Section 6(d).
“Effectiveness Date”
means, with respect to the Initial Registration Statement required
to be filed hereunder, the 120th calendar day following the date
hereof (or, in the event of a “full review” by the
Commission, the 180th calendar day
following the date hereof) and with respect to any additional
Registration Statements which may be required pursuant to Section
2(c) or Section 3(c), the 90th calendar day
following the date on which an additional Registration Statement is
required to be filed hereunder (or, in the event of a “full
review” by the Commission, the 180th calendar day
following the date such additional Registration Statement is
required to be filed hereunder); provided, however, that in the event the
Company is notified by the Commission that one or more of the above
Registration Statements will not be reviewed or is no longer
subject to further review and comments, the Effectiveness Date as
to such Registration Statement shall be the fifth Trading Day
following the date on which the Company is so notified if such date
precedes the dates otherwise required above, provided, further, if such Effectiveness
Date falls on a day that is not a Trading Day, then the
Effectiveness Date shall be the next succeeding Trading
Day.
“Effectiveness Period”
shall have the meaning set forth in Section 2(a).
“Event” shall have the
meaning set forth in Section 2(d).
“Event Date” shall have
the meaning set forth in Section 2(d).
“Filing Date” means, with
respect to the Initial Registration Statement required hereunder,
the 60th
calendar day following the date hereof and, with respect to any
additional Registration Statements which may be required pursuant
to Section 2(c) or Section 3(c), the earliest practical date on
which the Company is permitted by SEC Guidance to file such
additional Registration Statement related to the Registrable
Securities.
“Holder” or
“Holders” means the holder
or holders, as the case may be, from time to time of Registrable
Securities.
“Indemnified Party” shall
have the meaning set forth in Section 5(c).
“Indemnifying Party” shall
have the meaning set forth in Section 5(c).
“Initial Registration
Statement” means the initial Registration Statement
filed pursuant to this Agreement.
“Losses” shall have the
meaning set forth in Section 5(a).
“Plan of Distribution”
shall have the meaning set forth in Section 2(a).
“Prospectus” means the
prospectus included in a Registration Statement (including, without
limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rule 430A promulgated by
the Commission pursuant to the Securities Act), as amended or
supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities
covered by a Registration Statement, and all other amendments and
supplements to the Prospectus, including post-effective amendments,
and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.
“Registrable Securities”
means, as of any date of determination, (a) all Shares and (b) any
securities issued or then issuable upon any stock split, dividend
or other distribution, recapitalization or similar event with
respect to the foregoing; provided, however, that any such
Registrable Securities shall cease to be Registrable Securities
(and the Company shall not be required to maintain the
effectiveness of any, or file another, Registration Statement
hereunder with respect thereto) if (a) a Registration Statement
with respect to the sale of such Registrable Securities is declared
effective by the Commission under the Securities Act and such
Registrable Securities have been disposed of by the Holder in
accordance with such effective Registration Statement, (b) such
Registrable Securities have been previously sold in accordance with
Rule 144, or (c) such securities become eligible for resale without
volume or manner-of-sale restrictions and without current public
information pursuant to Rule 144 as set forth in a written opinion
letter to such effect, addressed, delivered and acceptable to the
Transfer Agent and the affected Holders, as reasonably determined
by the Company, upon the advice of counsel to the
Company.
“Registration Statement”
means any registration statement required to be filed hereunder
pursuant to Section 2(a) and any additional registration statements
contemplated by Section 2(c) or Section 3(c), including (in each
case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and
post-effective amendments, all exhibits thereto, and all material
incorporated by reference or deemed to be incorporated by reference
in any such registration statement.
“Rule
415” means Rule 415 promulgated by the Commission
pursuant to the Securities Act, as such Rule may be amended or
interpreted from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same
purpose and effect as such Rule.
“Rule 424” means Rule 424
promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended or interpreted from time to time, or any
similar rule or regulation hereafter adopted by the Commission
having substantially the same purpose and effect as such
Rule.
“Selling Stockholder
Questionnaire” shall have the meaning set forth in
Section 3(a).
“SEC Guidance” means (i)
any publicly-available written or oral guidance of the Commission
staff, or any comments, requirements or requests of the Commission
staff and (ii) the Securities Act and the rules and regulations
promulgated thereunder.
(a)
On or prior to each Filing Date, the Company shall prepare and file
with the Commission a Registration Statement covering the resale of
all the Registrable Securities that are not then registered on an
effective Registration Statement for an offering to be made on a
continuous basis pursuant to Rule 415. Each Registration
Statement filed hereunder shall be on Form S-1 and shall contain
(unless otherwise directed by at least 85% in interest of the
Holders) substantially the “Plan of Distribution”
attached hereto as Annex
A;provided,
however, that no
Holder shall be required to be named as an
“underwriter” without such Holder’s express prior
written consent;provided, further, that in the event the
Commission requires that a Holder be named as an
“underwriter” and such Holder does not so consent, the
Company shall not be required to include such Holder’s
Registrable Securities in a Registration Statement, notwithstanding
any provision to the contrary contained herein. Subject to the
terms of this Agreement, the Company shall use its best efforts to
cause a Registration Statement filed under this Agreement
(including, without limitation, under Section 3(c)) to be declared
effective under the Securities Act as promptly as possible after
the filing thereof, but in any event no later than the applicable
Effectiveness Date, and shall use its best efforts to keep such
Registration Statement continuously effective under the Securities
Act until all Registrable Securities covered by such Registration
Statement (i) have been sold, thereunder or pursuant to Rule 144,
or (ii) may be sold without volume or manner-of-sale restrictions
pursuant to Rule 144 and without the requirement for the Company to
be in compliance with the current public information requirement
under Rule 144, as determined by the counsel to the Company
pursuant to a written opinion letter to such effect, addressed and
acceptable to the Transfer Agent and the affected Holders (the
"Effectiveness
Period"). The Company shall
request effectiveness of a Registration Statement as of 5:00 p.m.
Eastern Time on a Trading Day. The Company shall immediately notify
the Holders via facsimile or by e-mail of the effectiveness of a
Registration Statement on the same Trading Day that the Company
telephonically confirms effectiveness with the Commission, which
shall be the date requested for effectiveness of such Registration
Statement. The Company shall, by 9:30 a.m. Eastern Time on the
Trading Day after the effective date of such Registration
Statement, file a final Prospectus with the Commission as required
by Rule 424. Failure to so notify the Holder within one (1) Trading
Day of such notification of effectiveness or failure to file a
final Prospectus as foresaid shall be deemed an Event under Section
2(d).
(b)
Notwithstanding the
registration obligations set forth in Section 2(a), if the
Commission informs the Company that all of the Registrable
Securities cannot, as a result of the application of Rule 415, be
registered for resale as a secondary offering on a single
registration statement, the Company agrees to promptly inform each
of the Holders thereof and use its commercially reasonable efforts
to file amendments to the Initial Registration Statement as
required by the Commission, covering the maximum number of
Registrable Securities permitted to be registered by the
Commission, on Form S-1, subject to the provisions of Section 2(d)
with respect to the payment of liquidated damages; provided, however, that prior to filing
such amendment, the Company shall be obligated to use diligent
efforts to advocate with the Commission for the registration of all
of the Registrable Securities in accordance with the SEC Guidance,
including without limitation, Compliance and Disclosure
Interpretation 612.09.
(c)
Notwithstanding
any other provision of this Agreement and subject to the payment of
liquidated damages pursuant to Section 2(d), if the Commission or
any SEC Guidance sets forth a limitation on the number of
Registrable Securities permitted to be registered on a particular
Registration Statement as a secondary offering (and notwithstanding
that the Company used diligent efforts to advocate with the
Commission for the registration of all or a greater portion of
Registrable Securities), unless otherwise directed in writing by a
Holder as to its Registrable Securities, the number of Registrable
Securities to be registered on such Registration Statement will be
reduced as follows:
a.
First,
the Company shall reduce or eliminate any securities to be included
by any Person other than a Holder;
b.
Second,
the Company shall reduce Registrable Securities represented by
Shares (applied, in the case that some Shares may be registered, to
the Holders on a pro rata basis based on the total number of
unregistered shares held by such Holders).
In
the event of a cutback hereunder, the Company shall give the Holder
at least five (5) Trading Days prior written notice along with the
calculations as to such Holder’s allotment. In the event the
Company amends the Initial Registration Statement in accordance
with the foregoing, the Company will use its best efforts to file
with the Commission, as promptly as allowed by Commission or SEC
Guidance provided to the Company or to registrants of securities in
general, one or more registration statements on Form S-1 or such
other form available to register for resale those Registrable
Securities that were not registered for resale on the Initial
Registration Statement, as amended.
(d) If: (i) the Initial
Registration Statement is not filed on or prior to its Filing Date
(if the Company files the Initial Registration Statement without
affording the Holders the opportunity to review and comment on the
same as required by Section 3(a) herein, the Company shall be
deemed to have not satisfied this clause (i)), or (ii) the Company
fails to file with the Commission a request for acceleration of a
Registration Statement in accordance with Rule 461 promulgated by
the Commission pursuant to the Securities Act, within five Trading
Days of the date that the Company is notified (orally or in
writing, whichever is earlier) by the Commission that such
Registration Statement will not be “reviewed” or will
not be subject to further review, or (iii) prior to the effective
date of a Registration Statement, the Company fails to file a
pre-effective amendment and otherwise respond in writing to
comments made by the Commission in respect of such Registration
Statement within ten (10) calendar days after the receipt of
comments by or notice from the Commission that such amendment is
required in order for such Registration Statement to be declared
effective, or (iv) a Registration Statement registering for resale
all of the Registrable Securities is not declared effective by the
Commission by the Effectiveness Date of the Initial Registration
Statement, or (v) after the effective date of a Registration
Statement, such Registration Statement ceases for any reason to
remain continuously effective as to all Registrable Securities
included in such Registration Statement, or the Holders are
otherwise not permitted to utilize the Prospectus therein to resell
such Registrable Securities, for more than ten (10) consecutive
calendar days or more than an aggregate of fifteen (15) calendar
days (which need not be consecutive calendar days) during any
12-month period, or (vi) any time during the period commencing from
the six (6) month anniversary of the date hereof and ending at such
time that all of the Registrable Securities may be sold without the
requirement for the Company to be in compliance with Rule 144(c)(1)
and otherwise without restriction or limitation pursuant to Rule
144, if the Company shall fail for any reason to satisfy the
current public information requirement under Rule 144(c) (any such
failure or breach being referred to as an “Event”, and for purposes
of clauses (i), (iv) and (vi), the date on which such Event occurs,
and for purpose of clause (ii) the date on which such five (5)
Trading Day period is exceeded, and for purpose of clause (iii) the
date which such ten (10) calendar day period is exceeded, and for
purpose of clause (v) the date on which such ten (10) or fifteen
(15) calendar day period, as applicable, is exceeded being referred
to as “Event
Date”), then except during any period of time in which
the Holders may sell the Registrable Securities pursuant to Rule
144 without volume limitations, in addition to any other rights the
Holders may have hereunder or under applicable law, on each such
Event Date and on each monthly anniversary of each such Event Date
(if the applicable Event shall not have been cured by such date)
until the applicable Event is cured, the Company shall pay to each
Holder an amount in cash, as liquidated damages and not as a
penalty, equal to the product of 1.0% multiplied by the aggregate
Subscription Amount paid by such Holder pursuant to the Purchase
Agreement with respect to the Registrable Securities affected by
such Event and held by such Holder on such Event Date and each
monthly anniversary thereof, up to a maximum of 6.0% of the
aggregate purchase price paid by such Holder pursuant to the
Purchase Agreement for such Registrable Securities. If the Company
fails to pay any liquidated damages pursuant to this Section in
full within seven days after the date payable, the Company will pay
interest thereon at a rate of 12% per annum (or such lesser maximum
amount that is permitted to be paid by applicable law) to the
Holder, accruing daily from the date such liquidated damages are
due until such amounts, plus all such interest thereon, are paid in
full. The liquidated damages pursuant to the terms hereof shall
apply on a daily pro rata basis for any portion of a month prior to
the cure of an Event.
(e) Notwithstanding
anything to the contrary contained herein, in no event shall the
Company be permitted to name any Holder or affiliate of a Holder as
any underwriter without the prior written consent of such Holder;
provided,
however, that in
the event the Commission requires that a Holder be named as an
“underwriter” and such Holder does not so consent, the
Company shall not be required to include such Holder’s
Registrable Securities in a Registration Statement, notwithstanding
any provision to the contrary contained herein.
3.
Registration
Procedures.
In
connection with the Company’s registration obligations
hereunder, the Company shall:
(a) Not less than two
(2) Trading Days prior to the filing of each Registration Statement
and not less than one (1) Trading Day prior to the filing of any
related Prospectus or any amendment or supplement thereto
(including any document that would be incorporated or deemed to be
incorporated therein by reference), the Company shall (i) furnish
to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be
incorporated by reference) will be subject to the review of such
Holders, and (ii) cause its officers and directors, counsel and
independent registered public accountants to respond to such
inquiries as shall be necessary, in the reasonable opinion of
respective counsel to each Holder, to conduct a reasonable
investigation within the meaning of the Securities Act.
Notwithstanding the above, the Company shall not be obligated to
provide the Holders advance copies of any universal shelf
registration statement registering securities in addition to those
required hereunder, or any Prospectus prepared thereto. The Company
shall not file a Registration Statement or any such Prospectus or
any amendments or supplements thereto to which the Holders of a
majority of the Registrable Securities shall reasonably object in
good faith, provided that, the Company is notified of such
objection in writing no later than two (2) Trading Days after the
Holders have been so furnished copies of a Registration Statement
or one (1) Trading Day after the Holders have been so furnished
copies of any related Prospectus or amendments or supplements
thereto. Each Holder agrees to furnish to the Company a completed
questionnaire in the form attached to this Agreement as
Annex B (a
“Selling Stockholder
Questionnaire”) on a date that is not less than two
(2) Trading Days prior to the Filing Date or by the end of the
fourth (4th) Trading Day
following the date on which such Holder receives draft materials in
accordance with this Section, whichever occurs first.
(b) (i) Prepare and
file with the Commission such amendments, including post-effective
amendments, to a Registration Statement and the Prospectus used in
connection therewith as may be necessary to keep a Registration
Statement continuously effective as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with
the Commission such additional Registration Statements in order to
register for resale under the Securities Act all of the Registrable
Securities, (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement (subject to the
terms of this Agreement), and, as so supplemented or amended, to be
filed pursuant to Rule 424, (iii) respond as promptly as reasonably
possible to any comments received from the Commission with respect
to a Registration Statement or any amendment thereto and provide as
promptly as reasonably possible to the Holders true and complete
copies of all correspondence from and to the Commission relating to
a Registration Statement (provided that, the Company shall excise
any information contained therein which would constitute material
non-public information regarding the Company or any of its
Subsidiaries), and (iv) comply in all material respects with the
applicable provisions of the Securities Act and the Exchange Act
with respect to the disposition of all Registrable Securities
covered by a Registration Statement during the applicable period in
accordance (subject to the terms of this Agreement) with the
intended methods of disposition by the Holders thereof set forth in
such Registration Statement as so amended or in such Prospectus as
so supplemented.
(c) If during the
Effectiveness Period, the number of Registrable Securities at any
time exceeds 100% of the number of shares of Common Stock then
registered in a Registration Statement, then the Company shall file
as soon as reasonably practicable, but in any case prior to the
applicable Filing Date, an additional Registration Statement
covering the resale by the Holders of not less than the number of
such Registrable Securities.
(d) Notify the Holders
of Registrable Securities to be sold (which notice shall, pursuant
to clauses (iii) through (vi) hereof, be accompanied by an
instruction to suspend the use of the Prospectus until the
requisite changes have been made) as promptly as reasonably
possible (and, in the case of (i)(A) below, not less than one (1)
Trading Day prior to such filing) and (if requested by any such
Person) confirm such notice in writing no later than one (1)
Trading Day following the day (i)(A) when a Prospectus or any
Prospectus supplement or post-effective amendment to a Registration
Statement is proposed to be filed, (B) when the Commission notifies
the Company whether there will be a “review” of such
Registration Statement and whenever the Commission comments in
writing on such Registration Statement, and (C) with respect to a
Registration Statement or any post-effective amendment, when the
same has become effective, (ii) of any request by the Commission or
any other federal or state governmental authority for amendments or
supplements to a Registration Statement or Prospectus or for
additional information, (iii) of the issuance by the Commission or
any other federal or state governmental authority of any stop order
suspending the effectiveness of a Registration Statement covering
any or all of the Registrable Securities or the initiation of any
Proceedings for that purpose, (iv) of the receipt by the Company of
any notification with respect to the suspension of the
qualification or exemption from qualification of any of the
Registrable Securities for sale in any jurisdiction, or the
initiation or threatening of any Proceeding for such purpose, (v)
of the occurrence of any event or passage of time that makes the
financial statements included in a Registration Statement
ineligible for inclusion therein or any statement made in a
Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any
material respect or that requires any revisions to a Registration
Statement, Prospectus or other documents so that, in the case of a
Registration Statement or the Prospectus, as the case may be, it
will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under
which they were made, not misleading, and (vi) of the occurrence or
existence of any pending corporate development with respect to the
Company that the Company believes may be material and that, in the
determination of the Company, makes it not in the best interest of
the Company to allow continued availability of a Registration
Statement or Prospectus, provided, however, in no event shall any
such notice contain any information which would constitute
material, non-public information regarding the Company or any of
its Subsidiaries.
(e) Use its best
efforts to avoid the issuance of, or, if issued, obtain the
withdrawal of (i) any order stopping or suspending the
effectiveness of a Registration Statement, or (ii) any suspension
of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the
earliest practicable moment.
(f) Furnish to each
Holder, without charge, at least one conformed copy of each such
Registration Statement and each amendment thereto, including
financial statements and schedules, all documents incorporated or
deemed to be incorporated therein by reference to the extent
requested by such Person, and all exhibits to the extent requested
by such Person (including those previously furnished or
incorporated by reference) promptly after the filing of such
documents with the Commission; provided, that any such item which
is available on the EDGAR system (or successor thereto) need not be
furnished in physical form.
(g) Subject to the
terms of this Agreement, the Company hereby consents to the use of
such Prospectus and each amendment or supplement thereto by each of
the selling Holders in connection with the offering and sale of the
Registrable Securities covered by such Prospectus and any amendment
or supplement thereto, except after the giving of any notice
pursuant to Section 3(d).
(h) The Company
shall cooperate with any broker-dealer through which a Holder
proposes to resell its Registrable Securities in effecting a filing
with the FINRA Corporate Financing Department pursuant to FINRA
Rule 5110, as requested by any such Holder, and the Company shall
pay the filing fee required by such filing within two (2) Business
Days of request therefor.
(i) Prior to any resale
of Registrable Securities by a Holder, use its commercially
reasonable efforts to register or qualify or cooperate with the
selling Holders in connection with the registration or
qualification (or exemption from the Registration or qualification)
of such Registrable Securities for the resale by the Holder under
the securities or Blue Sky laws of such jurisdictions within the
United States as any Holder reasonably requests in writing, to keep
each registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all
other acts or things reasonably necessary to enable the disposition
in such jurisdictions of the Registrable Securities covered by each
Registration Statement; provided, that, the Company shall not be
required to qualify generally to do business in any jurisdiction
where it is not then so qualified, subject the Company to any
material tax in any such jurisdiction where it is not then so
subject or file a general consent to service of process in any such
jurisdiction.
(j) If requested by a
Holder, cooperate with such Holder to facilitate the timely
preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a
Registration Statement, which certificates shall be free, to the
extent permitted by the Purchase Agreement, of all restrictive
legends, and to enable such Registrable Securities to be in such
denominations and registered in such names as any such Holder may
request.
(k) Upon the occurrence
of any event contemplated by Section 3(d), as promptly as
reasonably possible under the circumstances taking into account the
Company’s good faith assessment of any adverse consequences
to the Company and its stockholders of the premature disclosure of
such event, prepare a supplement or amendment, including a
post-effective amendment, to a Registration Statement or a
supplement to the related Prospectus or any document incorporated
or deemed to be incorporated therein by reference, and file any
other required document so that, as thereafter delivered, neither a
Registration Statement nor such Prospectus will contain an untrue
statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made,
not misleading. If the Company
notifies the Holders in accordance with clauses (iii) through (vi)
of Section 3(d) above to suspend the use of any Prospectus until
the requisite changes to such Prospectus have been made, then the
Holders shall suspend use of such Prospectus. The Company will use
its best efforts to ensure that the use of the Prospectus may be
resumed as promptly as is practicable. The Company shall be
entitled to exercise its right under this Section 3(k) to suspend
the availability of a Registration Statement and Prospectus,
subject to the payment of liquidated damages otherwise required
pursuant to Section 2(d), for a period not to exceed 60 calendar
days (which need not be consecutive days) in any 12-month
period.
(l) Comply with all
applicable rules and regulations of the Commission.
(m) The Company shall
use its best efforts to maintain eligibility for use of Form S-1
(or any successor form thereto) for the registration of the resale
of Registrable Securities.
(n) The Company may
require each selling Holder to furnish to the Company a certified
statement as to the number of shares of Common Stock beneficially
owned by such Holder and, if required by the Commission, the
natural persons thereof that have voting and dispositive control
over the shares. During any periods that the Company is unable to
meet its obligations hereunder with respect to the registration of
the Registrable Securities solely because any Holder fails to
furnish such information within three Trading Days of the
Company’s request, any liquidated damages that are accruing
at such time as to such Holder only shall be tolled and any Event
that may otherwise occur solely because of such delay shall be
suspended as to such Holder only, until such information is
delivered to the Company.
4.
Registration Expenses. All fees
and expenses incident to the performance of or compliance with,
this Agreement by the Company shall be borne by the Company whether
or not any Registrable Securities are sold pursuant to a
Registration Statement. The fees and expenses referred to in the
foregoing sentence shall include, without limitation, (i) all
registration and filing fees (including, without limitation, fees
and expenses of the Company’s counsel and independent
registered public accountants) (A) with respect to filings made
with the Commission, (B) with respect to filings required to be
made with any Trading Market on which the Common Stock is then
listed for trading, (C) in compliance with applicable state
securities or Blue Sky laws reasonably agreed to by the Company in
writing (including, without limitation, fees and disbursements of
counsel for the Company in connection with Blue Sky qualifications
or exemptions of the Registrable Securities) and (D) if not
previously paid by the Company in connection with an issuer filing
under FINRA Rule 5110, with respect to any filing that may be
required to be made by any broker through which a Holder intends to
make sales of Registrable Securities with FINRA pursuant to FINRA
Rule 5110, so long as the broker is receiving no more than a
customary brokerage commission in connection with such sale, (ii)
printing expenses (including, without limitation, expenses of
printing certificates for Registrable Securities), (iii) messenger,
telephone and delivery expenses, (iv) fees and disbursements of
counsel for the Company, (v) Securities Act liability insurance, if
the Company so desires such insurance, and (vi) fees and expenses
of all other Persons retained by the Company in connection with the
consummation of the transactions contemplated by this Agreement. In
addition, the Company shall be responsible for all of its internal
expenses incurred in connection with the consummation of the
transactions contemplated by this Agreement (including, without
limitation, all salaries and expenses of its officers and employees
performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the
listing of the Registrable Securities on any securities exchange as
required hereunder. In no event shall the Company be responsible
for any broker or similar commissions of any Holder or, except to
the extent provided for in the Transaction Documents, any legal
fees or other costs of the Holders.
(a) Indemnification by the Company.
The Company shall, notwithstanding any termination of this
Agreement, indemnify and hold harmless each Holder, the officers,
directors, members, partners, agents, brokers (including brokers
who offer and sell Registrable Securities as principal as a result
of a pledge or any failure to perform under a margin call of Common
Stock), investment advisors and employees (and any other Persons
with a functionally equivalent role of a Person holding such
titles, notwithstanding a lack of such title or any other title) of
each of them, each Person who controls any such Holder (within the
meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and the officers, directors, members, stockholders,
partners, agents and employees (and any other Persons with a
functionally equivalent role of a Person holding such titles,
notwithstanding a lack of such title or any other title) of each
such controlling Person, to the fullest extent permitted by
applicable law, from and against any and all losses, claims,
damages, liabilities, costs (including, without limitation,
reasonable attorneys’ fees) and expenses (collectively,
“Losses”), as incurred,
arising out of or relating to (1) any untrue or alleged untrue
statement of a material fact contained in a Registration Statement,
any Prospectus or any form of prospectus or in any amendment or
supplement thereto or in any preliminary prospectus, or arising out
of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the
statements therein (in the case of any Prospectus or supplement
thereto, in light of the circumstances under which they were made)
not misleading or (2) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act or any state
securities law, or any rule or regulation thereunder, in connection
with the performance of its obligations under this Agreement,
except to the extent, but only to the extent, that (i) such untrue
statements or omissions are based solely upon information regarding
such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information
relates to such Holder or such Holder’s proposed method of
distribution of Registrable Securities and was reviewed and
expressly approved in writing by such Holder expressly for use in a
Registration Statement, such Prospectus or in any amendment or
supplement thereto (it being understood that the Holder has
approved Annex A hereto for this purpose) or (ii) in the case of an
occurrence of an event of the type specified in Section
3(d)(iii)-(vi), the use by such Holder of an outdated, defective or
otherwise unavailable Prospectus after the Company has notified
such Holder in writing that the Prospectus is outdated, defective
or otherwise unavailable for use by such Holder and prior to the
receipt by such Holder of the Advice contemplated in Section 6(d).
The Company shall notify the Holders promptly of the institution,
threat or assertion of any Proceeding arising from or in connection
with the transactions contemplated by this Agreement of which the
Company is aware. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of such
indemnified person and shall survive the transfer of any
Registrable Securities by any of the Holders in accordance with
Section 6(h).
(b) Indemnification by Holders.
Each Holder shall, severally and not jointly, indemnify and hold
harmless the Company, its directors, officers, agents and
employees, each Person who controls the Company (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such
controlling Persons, to the fullest extent permitted by applicable
law, from and against all Losses, as incurred, to the extent
arising out of or based solely upon: (x) such Holder’s
failure to comply with any applicable prospectus delivery
requirements of the Securities Act through no fault of the Company
or (y) any untrue or alleged untrue statement of a material fact
contained in any Registration Statement, any Prospectus, or in any
amendment or supplement thereto or in any preliminary prospectus,
or arising out of or relating to any omission or alleged omission
of a material fact required to be stated therein or necessary to
make the statements therein (in the case of any Prospectus or
supplement thereto, in light of the circumstances under which they
were made) not misleading (i) to the extent, but only to the
extent, that such untrue statement or omission is contained in any
information so furnished in writing by such Holder to the Company
expressly for inclusion in such Registration Statement or such
Prospectus or (ii) to the extent, but only to the extent, that such
information relates to such Holder’s proposed method of
distribution of Registrable Securities and was reviewed and
expressly approved in writing by such Holder expressly for use in a
Registration Statement (it being understood that the Holder has
approved Annex A hereto for this purpose), such Prospectus or in
any amendment or supplement thereto or (iii) in the case of an
occurrence of an event of the type specified in Section
3(d)(iii)-(vi), to the extent, but only to the extent, related to
the use by such Holder of an outdated, defective or otherwise
unavailable Prospectus after the Company has notified such Holder
in writing that the Prospectus is outdated, defective or otherwise
unavailable for use by such Holder and prior to the receipt by such
Holder of the Advice contemplated in Section 6(d). In no event
shall the liability of any selling Holder under this Section 5(b)
be greater in amount than the dollar amount of the net proceeds
received by such Holder upon the sale of the Registrable Securities
giving rise to such indemnification obligation.
(c) Conduct of Indemnification
Proceedings. If any Proceeding shall be brought or asserted
against any Person entitled to indemnity hereunder (an
“Indemnified
Party”), such Indemnified Party shall promptly notify
the Person from whom indemnity is sought (the “Indemnifying Party”) in
writing, and the Indemnifying Party shall have the right to assume
the defense thereof, including the employment of counsel reasonably
satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof; provided,
that, the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or
liabilities pursuant to this Agreement, except (and only) to the
extent that it shall be finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or
further review) that such failure shall have materially and
adversely prejudiced the Indemnifying Party.
An
Indemnified Party shall have the right to employ separate counsel
in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense
of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the
Indemnifying Party shall have failed promptly to assume the defense
of such Proceeding and to employ counsel reasonably satisfactory to
such Indemnified Party in any such Proceeding, or (3) the named
parties to any such Proceeding (including any impleaded parties)
include both such Indemnified Party and the Indemnifying Party, and
counsel to the Indemnified Party shall reasonably believe that a
material conflict of interest is likely to exist if the same
counsel were to represent such Indemnified Party and the
Indemnifying Party (in which case, if such Indemnified Party
notifies the Indemnifying Party in writing that it elects to employ
separate counsel at the expense of the Indemnifying Party, the
Indemnifying Party shall not have the right to assume the defense
thereof and the reasonable fees and expenses of no more than one
separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written
consent, which consent shall not be unreasonably withheld or
delayed. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any
pending Proceeding in respect of which any Indemnified Party is a
party, unless such settlement includes an unconditional release of
such Indemnified Party from all liability on claims that are the
subject matter of such Proceeding.
Subject
to the terms of this Agreement, all reasonable fees and expenses of
the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing
to defend such Proceeding in a manner not inconsistent with this
Section) shall be paid to the Indemnified Party, as incurred,
within ten Trading Days of written notice thereof to the
Indemnifying Party; provided, that, the Indemnified Party shall
promptly reimburse the Indemnifying Party for that portion of such
fees and expenses applicable to such actions for which such
Indemnified Party is finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or
further review) not to be entitled to indemnification
hereunder.
(d) Contribution. If the
indemnification under Section 5(a) or 5(b) is unavailable to an
Indemnified Party or insufficient to hold an Indemnified Party
harmless for any Losses, then each Indemnifying Party shall
contribute to the amount paid or payable by such Indemnified Party,
in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party and Indemnified Party in connection with
the actions, statements or omissions that resulted in such Losses
as well as any other relevant equitable considerations. The
relative fault of such Indemnifying Party and Indemnified Party
shall be determined by reference to, among other things, whether
any action in question, including any untrue or alleged untrue
statement of a material fact or omission or alleged omission of a
material fact, has been taken or made by, or relates to information
supplied by, such Indemnifying Party or Indemnified Party, and the
parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such action, statement or
omission. The amount paid or payable by a party as a result of any
Losses shall be deemed to include, subject to the limitations set
forth in this Agreement, any reasonable attorneys’ or other
fees or expenses incurred by such party in connection with any
Proceeding to the extent such party would have been indemnified for
such fees or expenses if the indemnification provided for in this
Section was available to such party in accordance with its
terms.
The
parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 5(d) were determined by pro
rata allocation or by any other method of allocation that does not
take into account the equitable considerations referred to in the
immediately preceding paragraph. Notwithstanding the provisions of
this Section 5(d), no Holder shall be required to contribute
pursuant to this Section 5(d), in the aggregate, any amount in
excess of the amount by which the net proceeds actually received by
such Holder from the sale of the Registrable Securities subject to
the Proceeding exceeds the amount of any damages that such Holder
has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged
omission.
The
indemnity and contribution agreements contained in this Section are
in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.
(a) Remedies. In the event of a
breach by the Company or by a Holder of any of their respective
obligations under this Agreement, each Holder or the Company, as
the case may be, in addition to being entitled to exercise all
rights granted by law and under this Agreement, including recovery
of damages, shall be entitled to specific performance of its rights
under this Agreement. Each of the Company and each Holder agrees
that monetary damages would not provide adequate compensation for
any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the
event of any action for specific performance in respect of such
breach, it shall not assert or shall waive the defense that a
remedy at law would be adequate.
(b) No Piggyback on Registrations;
Prohibition on Filing Other Registration Statements. Except
as set forth on Schedule
6(b) attached hereto, neither the Company nor any of its
security holders (other than the Holders in such capacity pursuant
hereto) may include securities of the Company in any Registration
Statements other than the Registrable Securities. The Company shall
not file any other registration statements until all Registrable
Securities are registered pursuant to a Registration Statement that
is declared effective by the Commission, provided that this Section
6(b) (i) shall not prohibit the Company from filing amendments to
registration statements filed prior to the date of this Agreement
and (ii) shall not prohibit the Company from filing a shelf
registration statement on Form S-3 for a primary offering by the
Company, provided that the Company makes no offering of securities
pursuant to such shelf registration statement prior to the
effective date of the Registration Statement required hereunder
that includes all of the Registrable Securities.
(c) Compliance. Each Holder
covenants and agrees that it will comply with the prospectus
delivery requirements of the Securities Act as applicable to it
(unless an exemption therefrom is available) in connection with
sales of Registrable Securities pursuant to a Registration
Statement.
(d) Discontinued Disposition. By
its acquisition of Registrable Securities, each Holder agrees that,
upon receipt of a notice from the Company of the occurrence of any
event of the kind described in Section 3(d)(iii) through (vi), such
Holder will forthwith discontinue disposition of such Registrable
Securities under a Registration Statement until it is advised in
writing (the “Advice”) by the Company
that the use of the applicable Prospectus (as it may have been
supplemented or amended) may be resumed. The Company will use its
best efforts to ensure that the use of the Prospectus may be
resumed as promptly as is practicable. The Company agrees and
acknowledges that any periods during which the Holder is required
to discontinue the disposition of the Registrable Securities
hereunder shall be subject to the provisions of Section
2(d).
(e) Piggy-Back Registrations. If,
at any time during the Effectiveness Period, there is not an
effective Registration Statement covering all of the Registrable
Securities and the Company shall determine to prepare and file with
the Commission a registration statement relating to an offering for
its own account or the account of others under the Securities Act
of any of its equity securities, other than on Form S-4 or Form S-8
(each as promulgated under the Securities Act) or their then
equivalents relating to equity securities to be issued solely in
connection with any acquisition of any entity or business or equity
securities issuable in connection with the Company’s stock
option or other employee benefit plans, then the Company shall
deliver to each Holder a written notice of such determination and,
if within fifteen days after the date of the delivery of such
notice, any such Holder shall so request in writing, the Company
shall include in such registration statement all or any part of
such Registrable Securities such Holder requests to be registered;
provided,
however, that the
Company shall not be required to register any Registrable
Securities pursuant to this Section 6(e) that are eligible for
resale pursuant to Rule 144 (without volume restrictions or current
public information requirements) promulgated by the Commission
pursuant to the Securities Act or that are the subject of a then
effective Registration Statement.
(f) Amendments and Waivers. The
provisions of this Agreement, including the provisions of this
sentence, may not be amended, modified or supplemented, and waivers
or consents to departures from the provisions hereof may not be
given, unless the same shall be in writing and signed by the
Company and the Holders of a majority of the then outstanding
Registrable Securities. If a Registration Statement does not
register all of the Registrable Securities pursuant to a waiver or
amendment done in compliance with the previous sentence, then the
number of Registrable Securities to be registered for each Holder
shall be reduced pro rata among all Holders and each Holder shall
have the right to designate which of its Registrable Securities
shall be omitted from such Registration Statement. Notwithstanding
the foregoing, a waiver or consent to depart from the provisions
hereof with respect to a matter that relates exclusively to the
rights of a Holder or some Holders and that does not directly or
indirectly affect the rights of other Holders may be given only by
such Holder or Holders of all of the Registrable Securities to
which such waiver or consent relates; provided, however, that the provisions of
this sentence may not be amended, modified, or supplemented except
in accordance with the provisions of the first sentence of this
Section 6(f). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any
provision of this Agreement unless the same consideration also is
offered to all of the parties to this Agreement.
(g) Notices. Any and all notices or
other communications or deliveries required or permitted to be
provided hereunder shall be delivered as set forth in the Purchase
Agreement.
(h) Successors and Assigns. This
Agreement shall inure to the benefit of and be binding upon the
successors and permitted assigns of each of the parties and shall
inure to the benefit of each Holder. The Company may not assign
(except by merger) its rights or obligations hereunder without the
prior written consent of all of the Holders of the then outstanding
Registrable Securities. Each Holder may assign their respective
rights hereunder in the manner and to the Persons as permitted
under Section 5.7 of the Purchase Agreement.
(i) No Inconsistent Agreements.
Neither the Company nor any of its Subsidiaries has entered, as of
the date hereof, nor shall the Company or any of its Subsidiaries,
on or after the date of this Agreement, enter into any agreement
with respect to its securities, that would have the effect of
impairing the rights granted to the Holders in this Agreement or
otherwise conflicts with the provisions hereof. Except as set forth
on Schedule 6(i),
neither the Company nor any of its Subsidiaries has previously
entered into any agreement granting any registration rights with
respect to any of its securities to any Person that have not been
satisfied in full.
(j) Execution and Counterparts.
This Agreement may be executed in two or more counterparts, all of
which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In
the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file,
such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or
“.pdf” signature page were an original
thereof.
(k) Governing Law. All questions
concerning the construction, validity, enforcement and
interpretation of this Agreement shall be determined in accordance
with the provisions of the Purchase Agreement.
(l) Cumulative Remedies. The
remedies provided herein are cumulative and not exclusive of any
other remedies provided by law.
(m) Severability. If any term,
provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction to be invalid, illegal, void or
unenforceable, the remainder of the terms, provisions, covenants
and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated,
and the parties hereto shall use their commercially reasonable
efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such term,
provision, covenant or restriction. It is hereby stipulated and
declared to be the intention of the parties that they would have
executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.
(n) Headings. The headings in this
Agreement are for convenience only, do not constitute a part of the
Agreement and shall not be deemed to limit or affect any of the
provisions hereof.
(o) Independent Nature of Holders’
Obligations and Rights. The obligations of each Holder
hereunder are several and not joint with the obligations of any
other Holder hereunder, and no Holder shall be responsible in any
way for the performance of the obligations of any other Holder
hereunder. Nothing contained herein or in any other agreement or
document delivered at any closing, and no action taken by any
Holder pursuant hereto or thereto, shall be deemed to constitute
the Holders as a partnership, an association, a joint venture or
any other kind of group or entity, or create a presumption that the
Holders are in any way acting in concert or as a group or entity
with respect to such obligations or the transactions contemplated
by this Agreement or any other matters, and the Company
acknowledges that the Holders are not acting in concert or as a
group, and the Company shall not assert any such claim, with
respect to such obligations or transactions. Each Holder shall be
entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall
not be necessary for any other Holder to be joined as an additional
party in any proceeding for such purpose. The use of a single
agreement with respect to the obligations of the Company contained
was solely in the control of the Company, not the action or
decision of any Holder, and was done solely for the convenience of
the Company and not because it was required or requested to do so
by any Holder. It is expressly understood and agreed that each
provision contained in this Agreement is between the Company and a
Holder, solely, and not between the Company and the Holders
collectively and not between and among Holders.
********************
(Signature Pages Follow)
IN
WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first written above.
PARKERVISION, INC.
|
By:__________________________________________
Name:
Cynthia Poehlman
Title:
Chief Financial Officer
|
[SIGNATURE
PAGE OF HOLDERS FOLLOWS]
[SIGNATURE
PAGE OF HOLDERS TO PRKR RRA]
Name of
Holder: __________________________
Signature of Authorized Signatory of
Holder: __________________________
Name of
Authorized Signatory: _________________________
Title
of Authorized Signatory: __________________________
[SIGNATURE PAGES
CONTINUE]
Annex A
Plan of Distribution
Each
Selling Stockholder (the “Selling Stockholders”) of
the securities and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of
their securities covered hereby on the principal Trading Market or
any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may
be at fixed or negotiated prices. A Selling Stockholder may use any
one or more of the following methods when selling
securities:
●
ordinary brokerage
transactions and transactions in which the broker-dealer solicits
purchasers;
●
block trades in
which the broker-dealer will attempt to sell the securities as
agent but may position and resell a portion of the block as
principal to facilitate the transaction;
●
purchases by a
broker-dealer as principal and resale by the broker-dealer for its
account;
●
an exchange
distribution in accordance with the rules of the applicable
exchange;
●
privately
negotiated transactions;
●
settlement of short
sales;
●
in transactions
through broker-dealers that agree with the Selling Stockholders to
sell a specified number of such securities at a stipulated price
per security;
●
through the writing
or settlement of options or other hedging transactions, whether
through an options exchange or otherwise;
●
a combination of
any such methods of sale; or
●
any other method
permitted pursuant to applicable law.
The
Selling Stockholders may also sell securities under Rule 144 under
the Securities Act of 1933, as amended (the “Securities Act”), if
available, rather than under this prospectus.
Broker-dealers
engaged by the Selling Stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any
broker-dealer acts as agent for the purchaser of securities, from
the purchaser) in amounts to be negotiated, but, except as set
forth in a supplement to this Prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in
compliance with FINRA Rule 2440; and in the case of a principal
transaction a markup or markdown in compliance with FINRA
IM-2440.
In
connection with the sale of the securities or interests therein,
the Selling Stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn
engage in short sales of the securities in the course of hedging
the positions they assume. The Selling Stockholders may also sell
securities short and deliver these securities to close out their
short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The Selling Stockholders
may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or
more derivative securities which require the delivery to such
broker-dealer or other financial institution of securities offered
by this prospectus, which securities such broker-dealer or other
financial institution may resell pursuant to this prospectus (as
supplemented or amended to reflect such transaction).
The
Selling Stockholders and any broker-dealers or agents that are
involved in selling the securities may be deemed to be
“underwriters” within the meaning of the Securities Act
in connection with such sales. In such event, any commissions
received by such broker-dealers or agents and any profit on the
resale of the securities purchased by them may be deemed to be
underwriting commissions or discounts under the Securities Act.
Each Selling Stockholder has informed the Company that it does not
have any written or oral agreement or understanding, directly or
indirectly, with any person to distribute the
securities.
The
Company is required to pay certain fees and expenses incurred by
the Company incident to the registration of the securities. The
Company has agreed to indemnify the Selling Stockholders against
certain losses, claims, damages and liabilities, including
liabilities under the Securities Act.
Because
Selling Stockholders may be deemed to be “underwriters”
within the meaning of the Securities Act, they will be subject to
the prospectus delivery requirements of the Securities Act
including Rule 172 thereunder. In addition, any securities covered
by this prospectus which qualify for sale pursuant to Rule 144
under the Securities Act may be sold under Rule 144 rather than
under this prospectus. The Selling Stockholders have advised us
that there is no underwriter or coordinating broker acting in
connection with the proposed sale of the resale securities by the
Selling Stockholders.
We
agreed to keep this prospectus effective until the earlier of (i)
the date on which the securities may be resold by the Selling
Stockholders without registration and without regard to any volume
or manner-of-sale limitations by reason of Rule 144, without the
requirement for the Company to be in compliance with the current
public information under Rule 144 under the Securities Act or any
other rule of similar effect or (ii) all of the securities have
been sold pursuant to this prospectus or Rule 144 under the
Securities Act or any other rule of similar effect. The resale
securities will be sold only through registered or licensed brokers
or dealers if required under applicable state securities laws. In
addition, in certain states, the resale securities covered hereby
may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration
or qualification requirement is available and is complied
with.
Under
applicable rules and regulations under the Exchange Act, any person
engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to
the common stock for the applicable restricted period, as defined
in Regulation M, prior to the commencement of the distribution. In
addition, the Selling Stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations
thereunder, including Regulation M, which may limit the timing of
purchases and sales of securities of the common stock by the
Selling Stockholders or any other person. We will make copies of
this prospectus available to the Selling Stockholders and have
informed them of the need to deliver a copy of this prospectus to
each purchaser at or prior to the time of the sale (including by
compliance with Rule 172 under the Securities Act).
Annex
B
PARKERVISION, INC.
Selling Stockholder Notice and Questionnaire
The
undersigned beneficial owner of common stock (the
“Registrable
Securities”) of Parkervision, Inc., a Florida
corporation (the “Company”), understands
that the Company has filed or intends to file with the Securities
and Exchange Commission (the “Commission”) a
registration statement (the “Registration Statement”)
for the registration and resale under Rule 415 of the Securities
Act of 1933, as amended (the “Securities Act”), of the
Registrable Securities, in accordance with the terms of the
Registration Rights Agreement (the “Registration Rights
Agreement”) to which this document is annexed. A copy
of the Registration Rights Agreement is available from the Company
upon request at the address set forth below. All capitalized terms
not otherwise defined herein shall have the meanings ascribed
thereto in the Registration Rights Agreement.
Certain
legal consequences arise from being named as a selling stockholder
in the Registration Statement and the related prospectus.
Accordingly, holders and beneficial owners of Registrable
Securities are advised to consult their own securities law counsel
regarding the consequences of being named or not being named as a
selling stockholder in the Registration Statement and the related
prospectus.
NOTICE
The
undersigned beneficial owner (the “Selling Stockholder”) of
Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.
The
undersigned hereby provides the following information to the
Company and represents and warrants that such information is
accurate:
QUESTIONNAIRE
1. Name.
(a)
Full Legal Name of
Selling Stockholder
(b)
Full Legal Name of
Registered Holder (if not the same as (a) above) through which
Registrable Securities are held:
(c)
Full Legal Name of
Natural Control Person (which means a natural person who directly
or indirectly alone or with others has power to vote or dispose of
the securities covered by this Questionnaire):
2.
Address for Notices to Selling Stockholder:
|
|
|
Telephone:
|
Fax:
|
Contact
Person:
|
3.
Broker-Dealer Status:
(a)
Are you a
broker-dealer?
(b)
If
“yes” to Section 3(a), did you receive your Registrable
Securities as compensation for investment banking services to the
Company?
Note:
If “no”
to Section 3(b), the Commission’s staff has indicated that
you should be identified as an underwriter in the Registration
Statement.
(c)
Are you an
affiliate of a broker-dealer?
(d)
If you are an
affiliate of a broker-dealer, do you certify that you purchased the
Registrable Securities in the ordinary course of business, and at
the time of the purchase of the Registrable Securities to be
resold, you had no agreements or understandings, directly or
indirectly, with any person to distribute the Registrable
Securities?
Note:
If “no”
to Section 3(d), the Commission’s staff has indicated that
you should be identified as an underwriter in the Registration
Statement.
4.
Beneficial Ownership of Securities of the Company Owned by the
Selling Stockholder.
Except as set forth below in this Item 4, the undersigned is not
the beneficial or registered owner of any securities of the Company
other than the securities issuable pursuant to the Purchase
Agreement.
(a)
Type and Amount of
other securities beneficially owned by the Selling
Stockholder:
5.
Relationships with the Company:
Except as set forth below, neither the undersigned nor any of its
affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held
any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the
past three years.
State any
exceptions here:
The
undersigned agrees to promptly notify the Company of any
inaccuracies or changes in the information provided herein that may
occur subsequent to the date hereof at any time while the
Registration Statement remains effective.
By
signing below, the undersigned consents to the disclosure of the
information contained herein in its answers to Items 1 through 5
and the inclusion of such information in the Registration Statement
and the related prospectus and any
amendments or supplements thereto. The undersigned
understands that such information will be relied upon by the
Company in connection with the preparation or amendment of the
Registration Statement and the related prospectus and any
amendments or supplements thereto.
IN
WITNESS WHEREOF the undersigned, by authority duly given, has
caused this Notice and Questionnaire to be executed and delivered
either in person or by its duly authorized agent.
Name:
Title:
PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND
EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY
OVERNIGHT MAIL, TO:
Schedule 6(b)
Piggyback Registration Rights
TBD
ParkerVision, Inc.
WARRANT TO PURCHASE COMMON STOCK
Warrant
No. PV
2020-001
Number
of Shares: 5,000,000
(subject to adjustment)
Original Issue
Date: 02/28/2020
ParkerVision,
Inc., a Florida corporation (the “Company”), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, Aspire Capital
Fund, LLC, or its permitted registered assigns (the
“Holder”), is
entitled, subject to the terms set forth below, to purchase from
the Company up to a total of 5,000,000
shares of common stock, $0.01 par value per share (the
“Common
Stock”), of the Company (each such share, a
“Warrant Share”
and all such shares, the “Warrant Shares”) at an exercise
price per share equal to $0.74 per
share (as adjusted from time to time as provided in Section 9 herein, the
“Exercise
Price”), upon surrender of this warrant to purchase
Common Stock (including any warrants to purchase Common Stock
issued in exchange, transfer or replacement hereof, the
“Warrant”) at
any time and from time to time on or after the date hereof (the
“Original Issue
Date”) and through and including 5:30 P.M., New York
City time on the date that is five (5) years following the Original
Issue Date (the “Expiration
Date”), and subject to the following terms and
conditions:
1. Definitions. For purposes of
this Warrant, the following terms shall have the following
meanings:
(a) “Affiliate” of any Person means
any other Person directly or indirectly controlling, controlled by
or under common control with such Person.
(b) “Commission” means the United
States Securities and Exchange Commission and any successor entity
thereto.
(c) “Closing Sale Price” means, for
any security as of any date, the last trade price for such security
on the Principal Trading Market for such security, as reported by
Bloomberg Financial Markets, or, if such Principal Trading Market
begins to operate on an extended hours basis and does not designate
the last trade price, then the last trade price of such security
immediately prior to 4:00 P.M., New York City time, as reported by
Bloomberg Financial Markets, or if the foregoing do not apply, the
last trade price of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by
Bloomberg Financial Markets, or, if no last trade price is reported
for such security by Bloomberg Financial Markets, the average of
the bid and ask prices of any market makers for such security as
reported on OTC Pink (also known as the “pink sheets”)
by the OTC Markets, Inc. If the Closing Sale Price cannot be
calculated for a security on a particular date on any of the
foregoing bases, the Closing Sale Price of such security on such
date shall be the fair market value as mutually determined by the
Company and the Holder. If the Company and the Holder are unable to
agree upon the fair market value of such security, then the Board
of Directors of the Company shall use its good faith judgment to
determine the fair market value of such security on such date. The
Board of Directors’ determination shall be binding upon all
parties absent demonstrable error. All such determinations shall be
appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable
calculation period.
(d) “Person” means any natural person,
corporation, firm, joint venture, partnership, limited liability
company, association, enterprise, trust or other entity or
organization, or any government or political subdivision or any
agency, department or instrumentality thereof.
(e)
“Principal Trading Market” means
the trading market on which the Common Stock is primarily listed on
and quoted for trading, and which, as of the Original Issue Date
shall be the OTCQB Venture Market of the OTC Markets.
(f)
“Securities
Act” means the Securities Act of 1933, as
amended.
(g)
“Trading Day”
means a day on which the Principal Trading Market is open for
trading.
(h) “Transfer Agent” means American
Stock Transfer & Trust Company, the Company’s transfer
agent (or any successor transfer agent the Company may engage) for
the Common Stock, and the Company or its designee, with respect to
the Warrants.
2. Registration of Warrants. The
Company shall, or shall cause its Transfer Agent to, register this
Warrant, upon records to be maintained by the Company or Transfer
Agent for that purpose (the “Warrant Register”), in the name
of the record Holder (which shall include the initial Holder or, as
the case may be, any registered assignee to which this Warrant is
permissibly assigned hereunder) from time to time. The Company may
deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.
3. Registration of Transfers.
Subject to compliance with all applicable securities laws, the
Company shall, or shall cause its Transfer Agent to, register the
transfer of all or any portion of this Warrant in the Warrant
Register, upon surrender of this Warrant, and payment of all
applicable transfer taxes. Upon any such registration of transfer,
a new warrant to purchase Common Stock in substantially the form of
this Warrant (any such new warrant, a “New Warrant”) evidencing the
portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of
this Warrant not so transferred, if any, shall be issued to the
transferring Holder. The acceptance of the New Warrant by the
transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the
New Warrant that the Holder had in respect of this Warrant. The
Company shall, or shall cause its Transfer Agent to, prepare, issue
and deliver at the Company’s own expense any New Warrant
under this Section
3. Until due presentment for registration of transfer, the
Company may treat the registered Holder hereof as the owner and
holder of this Warrant for all purposes, and the Company shall not
be affected by any notice to the contrary.
4.
Exercise and Duration of
Warrants.
(a) All or any part of
this Warrant shall be exercisable by the registered Holder in any
manner permitted by this Warrant at any time and from time to time
on or after the Original Issue Date and through and including 5:30
P.M. New York City time, on the Expiration Date. At 5:30 P.M., New
York City time, on the Expiration Date, the portion of this Warrant
not exercised prior thereto shall be void and of no value and this
Warrant shall terminate and no longer be outstanding.
(b) The Holder may
exercise this Warrant by delivering to the Company (i) an exercise
notice, in the form attached as Schedule 1 hereto (the
“Exercise
Notice”), completed and duly signed, and (ii) payment
of the Exercise Price for the number of Warrant Shares as to which
this Warrant is being exercised (which may take the form of a
“net share exercise” if so indicated in the Exercise
Notice pursuant to Section
10 below), and the date on which the last of such items is
delivered to the Company (as determined in accordance with the
notice provisions hereof) is an “Exercise Date.” The Holder shall
not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise
Notice shall have the same effect as cancellation of the original
Warrant and issuance of a New Warrant to the Holder evidencing its
right to purchase the remaining number of Warrant Shares. For the
avoidance of doubt, the Company may not substitute, and the Holder
may not request, a cash payment in satisfaction of the
Company’s obligation to issue and deliver Warrant Shares
pursuant to an Exercise Notice, other than as specified in Sections
5(a), 9(c) or 12 of this Warrant.
5.
Delivery of Warrant
Shares.
(a) Upon exercise of
this Warrant, the Company shall promptly (but in no event later
than the earlier of the Standard Settlement Period (defined below)
or two (2) Trading Days after the Exercise Date), upon the request
of the Holder, credit such aggregate number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise to
the Holder’s or its designee’s balance account with The
Depository Trust Company (“DTC”) through its Deposit
Withdrawal Agent Commission system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program
(the “FAST
Program”) or if the certificates are required to bear
a legend regarding restriction on transferability, issue and
dispatch by overnight courier to the address as specified in the
Exercise Notice, a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the
number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise. The Holder, or any Person permissibly so
designated by the Holder to receive Warrant Shares, shall be deemed
to have become the holder of record of such Warrant Shares as of
the Exercise Date, irrespective of the date such Warrant Shares are
credited to the Holder’s DTC account or the date of delivery
of the certificates evidencing such Warrant Shares, as the case may
be.
(b) To the extent
permitted by law, the Company’s obligations to issue and
deliver Warrant Shares in accordance with and subject to the terms
hereof (including the limitations set forth in Section 11 below) are absolute
and unconditional, irrespective of any action or inaction by the
Holder to enforce the same, any waiver or consent with respect to
any provision hereof, the recovery of any judgment against any
Person or any action to enforce the same, or any setoff,
counterclaim, recoupment, limitation or termination, or any breach
or alleged breach by the Holder or any other Person of any
obligation to the Company or any violation or alleged violation of
law by the Holder or any other Person, and irrespective of any
other circumstance that might otherwise limit such obligation of
the Company to the Holder in connection with the issuance of
Warrant Shares. Nothing herein shall limit the Holder’s right
to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the
Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.
(c)
Except as set forth
in Section 5(d) hereof, the Warrants Shares to be issued under this
Warrant shall be issued without any restrictive legend. The Company
shall issue irrevocable instructions to its Transfer Agent, to
issue Common Stock in the name of the Holder for the Warrant Shares
and the Company warrants that the Warrant Shares shall be freely
transferable on the books and records of the Company.
Notwithstanding anything herein to the contrary, the Warrant Shares
shall not be required to contain any legend if such shares are
eligible for sale under Rule 144 of the Securities Act, or if such
legend is not required under other applicable requirements of the
Securities Act (including judicial interpretations and
pronouncements issued by the United Stated Securities &
Exchange Commission). The Company shall cause its counsel to issue
a legal opinion to the Company’s transfer agent or the Holder
if required by the Company’s transfer agent to effect the
removal of the legend hereunder, or if requested by the Purchaser,
respectively, provided that such legend is not required pursuant to
the foregoing provisions of this paragraph. The Company agrees that
at such time as such legend is no longer required under this
section (including, without limitation, following the effective
date of the Registration Statement), it will, no later than the
earlier of (i) two (2) Business Days and (ii) the number of
Business Days comprising the Standard Settlement Period (as defined
below) following the delivery by the Purchaser to the Company or
the Company’s transfer agent of a certificate representing
Warrant Shares issued with a restrictive legend (such date, the
“Legend Removal Date”), deliver or cause to be
delivered to the Holder such shares that are free from all
restrictive and other legends in such manner as directed by the
Holder. The Company may not make any notation on its records or
give instructions to the Company’s transfer agent that
enlarge the restrictions on transfer set forth in this section. The
Company shall pay all reasonable fees and expenses (including the
reasonable fees and expenses of legal counsel) relating to the
removal of the restrictive legends. As used herein, “Standard
Settlement Period” means the standard settlement period,
expressed in a number of Trading Days, on the Company’s
Principal Trading Market with respect to the Common Stock as in
effect on the date of delivery of a certificate representing
Warrant Shares, as the case may be, issued with a restrictive
legend.
(d) If the Company
files a registration statement to register any of its Common Stock
or other registerable securities, the Company shall also include
the Securities in such new registration statement in order to cover
the resale of the Securities by the Buyer. If any Warrant Shares
are issued and are neither registered for sale nor eligible for
sale pursuant to Rule 144 under the 1933 Act, they shall be issued
in certificated or restricted book-entry form and (subject to
Section 5 (c) hereof) shall bear a restrictive legend substantially
similar to the following:
THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT
AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE
144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION
OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES
LAWS.
6.
Charges, Taxes and Expenses.
Issuance and delivery of certificates for shares of Common Stock
upon exercise of this Warrant shall be made without charge to the
Holder for any issue or transfer tax, transfer agent fee or other
incidental tax or expense in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the
Company; provided,
however, that the
Company shall not be required to pay any tax that may be payable in
respect of any transfer involved in the registration of any
certificates for Warrant Shares or the Warrants in a name other
than that of the Holder or an Affiliate thereof. The Holder shall
be responsible for all other tax liability that may arise as a
result of holding or transferring this Warrant or receiving Warrant
Shares upon exercise hereof.
7. Replacement of Warrant. If this
Warrant is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and
upon cancellation hereof, or in lieu of and substitution for this
Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or
destruction (in such case) and, in each case, a customary and
reasonable indemnity and surety bond, if requested by the Company.
Applicants for a New Warrant under such circumstances shall also
comply with such other reasonable regulations and procedures and
pay such other reasonable third-party costs as the Company may
prescribe. If a New Warrant is requested as a result of a
mutilation of this Warrant, then the Holder shall deliver such
mutilated Warrant to the Company as a condition precedent to the
Company’s obligation to issue the New Warrant.
8.
Reservation and listing of Warrant
Shares. The Company covenants that it will at all times
while this Warrant is outstanding reserve and keep available out of
the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to
issue Warrant Shares upon exercise of this Warrant as herein
provided, the number of Warrant Shares that are initially issuable
and deliverable upon the exercise of this entire Warrant, free from
preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all
Warrant Shares so issuable and deliverable shall, upon issuance and
the payment of the applicable Exercise Price in accordance with the
terms hereof, be duly and validly authorized and issued, and fully
paid and nonassessable. The Company will take all such action as
may be reasonably necessary to assure that such shares of Common
Stock may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of any
securities exchange or automated quotation system upon which the
Common Stock may be listed. The Company shall promptly secure the
listing of all of the Warrant Shares upon each national securities
exchange and automated quotation system that
requires an application by the Company for listing, if any,
upon which shares of Common Stock are then listed (subject to
official notice of issuance) and shall maintain such listing, so long as any other shares
of Common Stock shall be so listed. The Company shall use its
reasonable best efforts to maintain the Common Stock’s
listing on the Principal Trading Market. Neither the Company nor
any of its Subsidiaries shall take any action that would be
reasonably expected to result in the delisting or suspension of the
Common Stock on the Principal Trading Market, unless the Common
Stock is immediately thereafter traded on the New York Stock
Exchange, the NYSE American, the Nasdaq Global Select Market, the
Nasdaq Global Market, the Nasdaq Capital Market, or the OTCQB
marketplace or OTCQX marketplace of the OTC Markets Group. The
Company shall pay all fees and expenses in connection with
satisfying its obligations under this Section.
9.
Certain Adjustments. The
Exercise Price and number of Warrant Shares issuable upon exercise
of this Warrant are subject to adjustment from time to time as set
forth in this Section
9.
(a) Stock Dividends and Splits. If
the Company, at any time while this Warrant is outstanding, (i)
pays a stock dividend on its Common Stock or otherwise makes a
distribution on any class of capital stock that is payable in
shares of Common Stock, (ii) subdivides its outstanding shares of
Common Stock into a larger number of shares of Common Stock, (iii)
combines its outstanding shares of Common Stock into a smaller
number of shares of Common Stock or (iv) issues by reclassification
of shares of capital stock any additional shares of Common Stock of
the Company, then in each such case the Exercise Price shall be
multiplied by a fraction, the numerator of which shall be the
number of shares of Common Stock outstanding immediately before
such event and the denominator of which shall be the number of
shares of Common Stock outstanding immediately after such event.
Any adjustment made pursuant to clause (i) of this paragraph shall
become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or
distribution; provided, however, that if such record
date shall have been fixed and such dividend is not fully paid on
the date fixed therefor, the Exercise Price shall be recomputed
accordingly as of the close of business on such record date and
thereafter the Exercise Price shall be adjusted pursuant to this
paragraph as of the time of actual payment of such dividends. Any
adjustment pursuant to clause (ii) or (iii) of this paragraph shall
become effective immediately after the effective date of such
subdivision or combination.
(b) Pro Rata Distributions. If the
Company, at any time while this Warrant is outstanding, distributes
to all holders of Common Stock for no consideration (i) evidences
of its indebtedness, (ii) any security (other than a distribution
of Common Stock covered by the preceding paragraph) or (iii) rights
or warrants to subscribe for or purchase any security, or (iv) any
other asset (in each case, “Distributed Property”), then,
upon any exercise of this Warrant that occurs after the record date
fixed for determination of stockholders entitled to receive such
distribution, the Holder shall be entitled to receive, in addition
to the Warrant Shares otherwise issuable upon such exercise (if
applicable), the Distributed Property that such Holder would have
been entitled to receive in respect of such number of Warrant
Shares had the Holder been the record holder of such Warrant Shares
immediately prior to such record date without regard to any
limitation on exercise contained therein.
(c) Fundamental Transactions. If,
at any time while this Warrant is outstanding (i) the Company
effects any merger or consolidation of the Company with or into
another Person, in which the Company is not the surviving entity or
the stockholders of the Company immediately prior to such merger or
consolidation do not own, directly or indirectly, at least 50% of
the voting power of the surviving entity immediately after such
merger or consolidation, (ii) the Company effects any sale to
another Person of all or substantially all of its assets in one or
a series of related transactions, (iii) pursuant to any tender
offer or exchange offer (whether by the Company or another Person),
holders of capital stock who tender shares representing more than
50% of the voting power of the capital stock of the Company and the
Company or such other Person, as applicable, accepts such tender
for payment, (iv) the Company consummates a stock purchase
agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with another Person whereby such other Person
acquires more than the 50% of the voting power of the capital stock
of the Company or (v) the Company effects any reclassification of
the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a
subdivision or combination of shares of Common Stock covered by
Section 9(a) above)
(in any such case, a “Fundamental Transaction”), then
following such Fundamental Transaction the Holder shall have the
right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been
entitled to receive upon the occurrence of such Fundamental
Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to
any limitations on exercise contained herein (the
“Alternate
Consideration”). The Company shall not effect any
Fundamental Transaction in which the Company is not the surviving
entity or the Alternate Consideration includes securities of
another Person unless prior to or simultaneously with the
consummation thereof, any successor to the Company, surviving
entity or other Person (including any purchaser of assets of the
Company) shall assume the obligation to deliver to the Holder, such
Alternate Consideration as, in accordance with the foregoing
provisions, the Holder may be entitled to receive, and the other
obligations under this Warrant.
(d) Number of Warrant Shares.
Simultaneously with any adjustment to the Exercise Price pursuant
to paragraph (a) of this Section 9, the number of
Warrant Shares that may be purchased upon exercise of this Warrant
shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the
increased or decreased number of Warrant Shares shall be the same
as the aggregate Exercise Price in effect immediately prior to such
adjustment.
(e) Calculations. All calculations
under this Section
9 shall be made to the nearest cent or the nearest share, as
applicable.
(f) Notice of Adjustments. Upon the
occurrence of each adjustment pursuant to this Section 9, the Company at its
expense will, at the written request of the Holder, promptly
compute such adjustment, in good faith, in accordance with the
terms of this Warrant and prepare a certificate setting forth such
adjustment, including a statement of the adjusted Exercise Price
and adjusted number or type of Warrant Shares or other securities
issuable upon exercise of this Warrant (as applicable), describing
the transactions giving rise to such adjustments and showing in
detail the facts upon which such adjustment is based. Upon written
request, the Company will promptly deliver a copy of each such
certificate to the Holder and to the Company’s transfer
agent.
(g) Notice of Corporate Events. If,
while this Warrant is outstanding, the Company (i) declares a
dividend or any other distribution of cash, securities or other
property in respect of its Common Stock, including, without
limitation, any granting of rights or warrants to subscribe for or
purchase any capital stock of the Company or any subsidiary, (ii)
authorizes or approves, enters into any material definitive
agreement contemplating or solicits stockholder approval for any
Fundamental Transaction or (iii) authorizes the voluntary
dissolution, liquidation or winding up of the affairs of the
Company, then, except if such notice and the contents thereof shall
be deemed to constitute material non-public information, the
Company shall deliver to the Holder a notice of such transaction at
least ten (10) days prior to the applicable record or effective
date on which a Person would need to hold Common Stock in order to
participate in or vote with respect to such transaction;
provided, however, that the failure to deliver
such notice or any defect therein shall not affect the validity of
the corporate action required to be described in such notice. In
addition, if while this Warrant is outstanding, if the Company
enters into any material definitive agreement contemplating or
solicits stockholder approval for any Fundamental Transaction
contemplated by Section
9(c), other than a Fundamental Transaction under clause
(iii) of Section
9(c), the Company shall deliver to the Holder a notice of
such Fundamental Transaction at least fifteen (15) days prior to
the date such Fundamental Transaction is consummated. To the extent
that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of
its subsidiaries, the Holder shall keep such information
confidential until the Company shall file such notice with the
Commission pursuant to a Current Report on Form 8-K.
10. Payment of Exercise Price.
Notwithstanding anything contained herein to the contrary, the
Holder may, in its sole discretion, satisfy its obligation to pay
the Exercise Price through a “net share exercise”, in
which event the Company shall issue to the Holder the number of
Warrant Shares determined as follows:
X = Y
[(A-B)/A]
where:
“X”
equals the number
of Warrant Shares to be issued to the Holder;
“Y”
equals the total
number of Warrant Shares with respect to which this Warrant is then
being exercised;
“A”
the Closing Sale
Prices of the shares of Common Stock on the date immediately
preceding the Exercise Date; and
B” equals
the Exercise Price then in effect for the applicable Warrant Shares
at the time of such exercise.
For
purposes of Rule 144 promulgated under the Securities Act, it is
intended, understood and acknowledged that the Warrant Shares
issued in a “cashless exercise” transaction shall be
deemed to have been acquired by the Holder, and the holding period
for the Warrant Shares shall be deemed to have commenced, on the
date this Warrant was originally issued (provided that the
Commission continues to take the position that such treatment is
proper at the time of such exercise).
Notwithstanding
anything herein to the contrary, on the Expiration Date, any
remaining part of this Warrant shall be automatically exercised via
net share exercise pursuant to this Section 10 without any action
being required on the part of the Holder. The Company shall
promptly deliver to the Holder the calculation made pursuant to the
preceding sentence, together with any Warrant Shares to which such
Holder is entitled.
11. Limitations on
Exercise.
(a) Notwithstanding
anything to the contrary contained herein, the number of Warrant
Shares that may be acquired by the Holder upon any exercise of this
Warrant (or otherwise in respect hereof) shall be limited to the
extent necessary to ensure that, following such exercise (or other
issuance), the total number of shares of Common Stock then
beneficially owned by the Holder and its Affiliates and any other
Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of Section 13(d) of
the Securities Exchange Act of 1934, as amended (the
“Exchange
Act”), does not exceed 9.99% of the total number of
then issued and outstanding shares of Common Stock (including for
such purpose the shares of Common Stock issuable upon such
exercise), it being acknowledged by the Holder that the Company is
not representing to such Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder and such Holder is solely
responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this
Section 11(a)
applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder and its
Affiliates) and of which a portion of this Warrant is exercisable
shall be in the sole discretion of a Holder, and the submission of
a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation
to other securities owned by such Holder and its Affiliates) and of
which portion of this Warrant is exercisable, in each case subject
to such aggregate percentage limitation, and the Company shall have
no obligation to verify or confirm the accuracy of such
determination. In addition, a determination under this Section 11(a) as to any group
status shall be determined by the Holder in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 11(a), in determining
the number of outstanding shares of Common Stock, the Holder may
rely on the number of outstanding shares of Common Stock as
reflected in (x) the Company’s most recent Form 10-Q or Form
10-K, as the case may be, (y) a more recent public announcement by
the Company that contains such number of shares or (z) any other
notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written
request of the Holder, the Company shall within one (1) Trading Day
confirm orally and in writing to such Holder the number of shares
of Common Stock then outstanding. By written notice to the Company,
which will not be effective until the sixty-first (61st) day after
such notice is delivered to the Company, the Holder may waive the
provisions of this Section
11(a) (but such waiver will not affect any other holder) to
change the beneficial ownership limitation to such percentage of
the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant as the Holder shall determine, in its sole
discretion, and the provisions of this Section 11(a) shall continue to
apply. Upon such a change by a Holder of the beneficial ownership
limitation from such 9.99% limitation to such other percentage
limitation, the beneficial ownership limitation may not be further
waived by such Holder without first providing the minimum notice
required by this Section
11(a). Notwithstanding the foregoing, at any time following
notice of a Fundamental Transaction under Section 9(g)(ii) with respect
to a Section
9(c)(iii) Fundamental Transaction, the Holder may waive
and/or change the beneficial ownership limitation effective
immediately upon written notice to the Company and may reinstitute
a beneficial ownership limitation at any time thereafter effective
immediately upon written notice to the Company.
(b) Notwithstanding
anything to the contrary contained herein, including Section 11(a), the Company
shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant for a number of Warrant
Shares in excess of that number of Warrant Shares which, upon
giving effect to such exercise, would cause (i) the aggregate
number of shares of Common Stock beneficially owned by the Holder
and its Affiliates and any other Persons whose beneficial ownership
of Common Stock would be aggregated with the Holder’s for
purposes of Section 13(d) of the Exchange Act, to exceed 19.99% of
the total number of issued and outstanding shares of Common Stock
of the Company following such exercise, or (ii) the combined voting
power of the securities of the Company beneficially owned by the
Holder and its Affiliates and any other Persons whose beneficial
ownership of Common Stock would be aggregated with the
Holder’s for purposes of Section 13(d) of the Exchange Act to
exceed 19.99% of the combined voting power of all of the securities
of the Company then outstanding following such exercise. For
purposes of this Section
11(b), the aggregate number of shares of Common Stock or
voting securities beneficially owned by the Holder and its
Affiliates and any other Persons whose beneficial ownership of
Common Stock would be aggregated with the Holder’s for
purposes of Section 13(d) of the Exchange Act shall include the
shares of Common Stock issuable upon the exercise of this Warrant
with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be
issuable upon (x) exercise of the remaining unexercised and
non-cancelled portion of this Warrant by the Holder and (y)
exercise or conversion of the unexercised, non-converted or non-
cancelled portion of any other securities of the Company that do
not have voting power (including without limitation any securities
of the Company which would entitle the holder thereof to acquire at
any time Common Stock, including without limitation any debt,
preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock), is
subject to a limitation on conversion or exercise analogous to the
limitation contained herein and is beneficially owned by the Holder
or any of its Affiliates and other Persons whose beneficial
ownership of Common Stock would be aggregated with the
Holder’s for purposes of Section 13(d) of the Exchange
Act.
(c) This Section 11 shall not restrict
the number of shares of Common Stock which a Holder may receive or
beneficially own in order to determine the amount of securities or
other consideration that such Holder may receive in the event of a
Fundamental Transaction as contemplated in Section 9 of this
Warrant.
12. No Fractional Shares. No
fractional Warrant Shares will be issued in connection with any
exercise of this Warrant. In lieu of any fractional shares that
would otherwise be issuable, the number of Warrant Shares to be
issued shall be rounded down to the next whole number and the
Company shall pay the Holder in cash the fair market value (based
on the Closing Sale Price) for any such fractional
shares.
13. Notices. Any and all notices or
other communications or deliveries hereunder (including, without
limitation, any Exercise Notice) shall be in writing and shall be
deemed given and effective on the earliest of (i) the date of
transmission, if such notice or communication is delivered via
facsimile or confirmed e-mail at the facsimile number or e-mail
address specified in the books and records of the Transfer Agent
prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the
next Trading Day after the date of transmission, if such notice or
communication is delivered via facsimile or confirmed e-mail at the
facsimile number or e-mail address specified in the books and
records of the Transfer Agent on a day that is not a Trading Day or
later than 5:30 P.M., New York City time, on any Trading Day, (iii)
the Trading Day following the date of mailing, if sent by
nationally recognized overnight courier service specifying next
business day delivery, or (iv) upon actual receipt by the Person to
whom such notice is required to be given, if by hand
delivery.
14. Warrant Agent. The Company
shall initially serve as warrant agent under this Warrant. Upon
thirty (30) days’ notice to the Holder, the Company may
appoint a new warrant agent. Any corporation into which the Company
or any new warrant agent may be merged or any corporation resulting
from any consolidation to which the Company or any new warrant
agent shall be a party or any corporation to which the Company or
any new warrant agent transfers substantially all of its corporate
trust or shareholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such
successor warrant agent shall promptly cause notice of its
succession as warrant agent to be mailed (by first class mail,
postage prepaid) to the Holder at the Holder’s last address
as shown on the Warrant Register.
(a) No Rights as a Stockholder. The
Holder, solely in such Person’s capacity as a holder of this
Warrant, shall not be entitled to vote or receive dividends or be
deemed the holder of share capital of the Company for any purpose,
nor shall anything contained in this Warrant be construed to confer
upon the Holder, solely in such Person’s capacity as the
Holder of this Warrant, any of the rights of a stockholder of the
Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, amalgamation,
conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the
issuance to the Holder of the Warrant Shares which such Person is
then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as
imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a stockholder of
the Company, whether such liabilities are asserted by the Company
or by creditors of the Company.
(b)
Authorized
Shares
(i) Except and to the
extent as waived or consented to by the Holder, the Company shall
not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying
out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set
forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (a) not increase the
par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value,
(b) take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant, and
(c) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof as may be necessary to enable the
Company to perform its obligations under this Warrant.
(ii) Before
taking any action which would result in an adjustment in the number
of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or
exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction
thereof.
(c) Successors and Assigns. Subject
to the restrictions on transfer set forth in this Warrant and
compliance with applicable securities laws, this Warrant may be
assigned by the Holder. This Warrant may not be assigned by the
Company without the written consent of the Holder except to a
successor in the event of a Fundamental Transaction. This Warrant
shall be binding on and inure to the benefit of the Company and the
Holder and their respective successors and assigns. Subject to the
preceding sentence, nothing in this Warrant shall be construed to
give to any Person other than the Company and the Holder any legal
or equitable right, remedy or cause of action under this
Warrant.
(d) Amendment and Waiver. Except as
otherwise provided herein, the provisions of the Warrants may be
amended and the Company may take any action herein prohibited, or
omit to perform any act herein required to be performed by it, only
if the Company has obtained the written consent of the Holders of
Warrants representing no less than a majority of the Warrant Shares
obtainable upon exercise of the Warrants then
outstanding.
(e) Acceptance. Receipt of this
Warrant by the Holder shall constitute acceptance of and agreement
to all of the terms and conditions contained herein.
(f) Governing Law; Jurisdiction.
ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT
AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND
CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
ILLINOIS WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL
COURTS SITTING IN THE CITY OF CHICAGO FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO
THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY
IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. NOTHING CONTAINED HEREIN SHALL BE
DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER
PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES
ALL RIGHTS TO A TRIAL BY JURY.
(g) Headings. The headings herein
are for convenience only, do not constitute a part of this Warrant
and shall not be deemed to limit or affect any of the provisions
hereof.
(h) Severability. In case any one
or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Warrant shall not in any
way be affected or impaired thereby, and the Company and the Holder
will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute
therefor, and upon so agreeing, shall incorporate such substitute
provision in this Warrant.
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated
above.
PARKERVISION,
INC.
By: /s/
Jeffrey Parker
Title: CEO
Schedule
1
FORM OF
NOTICE OF EXERCISE
Ladies
and Gentlemen:
(1)
The undersigned is
the Holder of Warrant No. _____ (the "Warrant") issued by
ParkerVision, Inc., a Florida corporation (the "Company").
Capitalized terms used herein and not otherwise defined herein have
the respective meanings set forth in the Warrant.
(2)
The undersigned
hereby exercises its right to purchase _____Warrant Shares pursuant
to the Warrant.
(3)
The Holder intends
that payment of the Exercise Price shall be made as (check one or
both):
□
a "cash exercise"
with respect to Warrant Shares; and/or
□
a "net share exercise" pursuant to Section 10 of the Warrant with
respect to
(4)
In the event that
the Holder has elected a "cash exercise" with respect to some or
all of the Warrant Shares, the Holder shall pay the Exercise Price
in the sum of $_____ to the Company in accordance with the terms of
the Warrant.
(5)
Pursuant to this
Exercise Notice, the Company shall deliver to the Holder Warrant
Shares determined in accordance with the terms of the Warrant.
Please issue (check applicable box):
□
A certificate of
certificates representing the Holder's Warrant Shares in the name
of the undersigned or in the following name: _____
□
The Holder's Warrant Shares in electronic form to the following
account:
Name
and Contact for Broker: _____
Broker
no: _____
Account
no: _____
Account
holder: _____
(6)
By its delivery of
this Exercise Notice, the undersigned represents and warrants to
the Company that in giving effect to the exercise evidenced hereby
the Holder will not beneficially own in excess of the number of
shares of Common Stock (as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended) permitted
to be owned under Section 11(a) or Section 11(b), as applicable, of
the Warrant to which this notice relates.
Name of
Holder: _____
By:
_____
Name:
_____
Title:
_____
(Signature
must conform in all respects to name of Holder as specified on the
face of the Warrant)